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ABSTRACT 
 
The renin-angiotensin system (RAS) plays a pivotal role in the pathogenesis of 
hypertension, myocardial infarction, stroke, renal failure, and diabetic vascular 
complications. Besides the classical regulatory effects on blood pressure, sodium 
excretion, and aldosterone secretion, evidence is now accumulating supporting the 
notion that RAS may also induce an inflammatory response and oxidative stress in the 
vascular wall by non-hemodynamic mechanisms. The present series of studies was 
conducted to investigate the mechanisms of angiotensin II (Ang II)-induced inflammation 
and vascular dysfunction, focusing especially on the role of oxidative stress and 
cyclooxygenase (COX) in the pathogenesis.  
 
Two transgenic rats with increased local RAS activity: namely double transgenic rats 
harboring human renin and human angiotensinogen genes (dTGRs) (4 weeks old), and 
transgenic rats harboring the mouse renin-2 gene (mREN2 rats) (8 weeks old), as well 
as spontaneously diabetic Goto-Kakizaki (GK) rats (5-6 weeks old), were used as 
experimental animal models. The effects of prolonged treatment with the AT1 receptor 
antagonists valsartan and losartan, a high-sodium (HS) diet, the selective 
cyclooxygenase-2 (COX-2) inhibitor MF-tricyclic, and the non-selective COX-1/COX-2 
inhibitor sulindac were evaluated in the pathogenesis of Ang II-induced inflammation and 
vascular injury. Blood pressure was recorded either indirectly by the tail-cuff method or 
directly by radiotelemetry. Arterial contractile and relaxation responses were examined 
ex vivo by use of mesenteric, renal, or aortic rings. Inflammatory response in the kidney 
and heart was evaluated by immunohistochemistry. COX mRNA and protein 
expressions were quantified by RT-PCR and immunohistochemistry, respectively. As 
indirect markers of oxidative stress, serum 8-isoprostaglandin F
2α
 concentrations, as well 
as tissue xanthine oxidoreductase (XOR) activity were measured.  
 
Ang II induced endothelial dysfunction via AT1 receptor stimulation. This Ang II-induced 
endothelial dysfunction was associated with increased oxidative stress, which was 
partially mediated via XOR in dTGRs. In GK rats, increased RAS activity was also 
involved in the pathogenesis of endothelial dysfunction and vascular inflammation. An 
HS diet in these rats elevated blood pressure, and aggravated cardiac hypertrophy, 
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endothelial dysfunction, inflammatory response, vascular injury, and oxidative stress. 
The AT1 receptor antagonist valsartan prevented the salt-induced inflammatory 
response and oxidative stress in GK rats by blood pressure-independent mechanisms. 
In mREN2 rats, renal COX-2 mRNA and protein expressions were down-regulated. 
Neither MF-tricyclic nor sulindac prevented an Ang II-induced inflammatory response, 
endothelial dysfunction, or vascular/tissue injury in these rats. In contrast, both drugs 
raised blood pressure and albuminuria to a similar extent in mREN2 rats. However, the 
therapeutic effects of the AT1 receptor antagonist losartan on Ang II-induced 
hypertension, inflammatory response, endothelial dysfunction, and tissue morphology, 
were not interfered with by concurrent COX inhibition.  
 
Taken together, our findings indicate that (1) oxidative stress is involved in the 
pathogenesis of Ang II-induced vascular dysfunction and inflammatory response, (2) the 
detrimental effects of Ang II on vascular function and tissue morphology are mediated 
via the AT1 receptor, and (3) COX does not play a central role in the pathogenesis of 
Ang II-induced inflammation and vascular injury. 
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1. INTRODUCTION 
 
Hypertension is one of the most important risk factors for arteriosclerosis, myocardial 
infarction, stroke, and renal failure (Collins et al., 1990; MacMahon et al., 1990; Perry et 
al., 1995). Approximately 24% of the population in industrialized countries and more 
than half the population aged over 65 years suffers from hypertension (Ruoff, 1998). 
Despite the enormous amount of work carried out in past decades to explore the 
mechanisms involved in the pathogenesis of hypertension, the cause of high blood 
pressure in 95% of the patients remains unknown.  
 
Some epidemiological evidence exists that hypertensive patients with activated RAS 
have a higher risk for myocardial infarction than other forms of hypertension (Alderman 
et al., 1991; Meade et al., 1993; Alderman, 1995; Laragh, 1995). Furthermore, treatment 
of hypertensive patients with angiotensin-converting enzyme (ACE) inhibitors and Ang II 
type I (AT1) receptor antagonists reduces the incidence of myocardial infarctions and 
mortality (Yusuf et al., 1992; Pitt, 1994; Timmermans & Smith, 1996; Gavras, 1997), 
indicating the central role of RAS in the pathogenesis of hypertension and in its 
complications. 
 
Historically, Ang II, the key effector of RAS, was considered to be a circulating hormone 
that regulates blood pressure, aldosterone secretion, and salt reabsorption. At the 
present, it is generally accepted that Ang II is also formed locally in several tissues, such 
as vascular wall, heart, kidney, and brain (for review, see Bader et al., 2001). Ang II 
regulates cellular growth, proliferation, and inflammatory responses. The production of 
Ang II within the arterial wall is also important in the regulation of arterial tone. The 
presence of an inflammatory response in the arterial wall has been described in different 
vascular diseases, including hypertension and atherosclerosis (Ross, 1999), and in 
hypertensive end-organ damage (Mervaala et al., 1999b).  
 
Non-insulin-dependent diabetes mellitus (NIDDM, type II DM) is also a prevalent disease 
in the western world, commonly accompanied by hypertension, dyslipidemia, and 
vascular complications (Grundy et al., 1999). About 80% of the patients with NIDDM are 
hypertensive at the time of diagnosis (Grundy et al., 1999). Most diabetic patients die 
INTRODUCTION 
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from macrovascular complications. The mechanisms of the pathogenesis of diabetic 
vascular disease, however, still remain unclear (for review, see Semenkovich & 
Heinecke, 1997). Recent clinical studies have revealed that both ACE inhibitors and AT1 
receptor antagonists prevent the development of diabetic complications, indicating the 
importance of RAS in the pathogenesis (Mogyorosi & Sonkodi, 1999; Brenner et al., 
2001). 
 
The present study was designed to explore the underlying mechanisms of Ang II-
induced vascular dysfunction and inflammation in three animal models: double 
transgenic rats harboring human renin and human angiotensinogen genes (dTGRs), 
mouse transgenic rats harboring the mouse renin-2 gene (mREN2 rats), and 
spontaneously diabetic Goto-Kakizaki (GK) rats. Prolonged treatment with AT1 receptor 
antagonists, or selective and non-selective COX inhibitors or both was used to clarify the 
pathophysiological role of Ang II and COX isoenzymes. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Renin-angiotensin system (RAS) 
 
In past decades, RAS has been extensively studied as an important mediator of 
hypertension and hypertensive cardiac and renal damage. Originally, RAS was regarded 
as a circulating hormone system. Recent studies, however, have demonstrated the 
existence of local RAS in many tissues including the brain, kidney, adrenal cortex, heart, 
and blood vessel wall (for review, see Bader et al., 2001). Here, RAS acts through 
paracrine-autocrine mechanisms (Rothermund & Paul, 1998). Tissue RAS is activated in 
pathophysiological situations, and local synthesis of Ang II appears to contribute to 
altered tissue function and morphology (Hirsch et al., 1990). According to the original 
view, when the kidneys sense diminished effective arterial blood flow, renin is released 
from the macula densa of the juxtaglomerular apparatus. Once in the circulation, renin 
catalyzes the conversion of angiotensinogen which is synthesized in the liver, to 
angiotensin I (Ang I). Ang I is further converted to octapeptide Ang II, a key effector of 
RAS, by angiotensin-converting enzyme (ACE). ACE is primarily an endothelial-bound 
enzyme with particularly high concentrations in the lung (for review, see Bader et al., 
2001). 
 
Non-ACE pathways have been suggested as catalyzing the production of Ang II within 
tissues, including cathepsin G, chymostatin-sensitive angiotensin II-generating enzyme 
(CAGE), chymase, tonin, and tissue plasminogen activator (t-PA) (Dzau, 1988; Dzau et 
al., 1993; Gibbons, 1993; Gibbons & Dzau, 1994). Non-ACE pathways are functionally 
important in human blood vessels, as recently demonstrated in large and small 
resistance arteries from healthy human volunteers (Padmanabhan et al., 1999). In 
humans, at least 40% of total Ang II is formed by non-ACE pathways (for review, see 
Hollenberg et al., 1998), suggesting that full suppression of the RAS cannot be achieved 
by ACE inhibition alone (Petrie et al., 2001). However, in rats, ACE seems to be the 
most important enzyme for Ang II formation (Okunishi et al., 1993) (Figure 1). 
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Ang II exerts its effects via binding to specific receptors on the cell surface. Ang II 
receptors of the cardiovascular system are divided into two main subtypes: Ang II type 1 
(AT1) and 2 (AT2) receptors, which are specifically blocked by AT1 receptor antagonists, 
e.g., losartan and valsartan (for review, see de Gasparo et al., 2000). In rodents, AT1 
receptors are further divided into two subtypes, AT1a and AT1b (Kakar et al., 1992). The 
AT1 receptor is a G-protein-coupled receptor. The molecular and cellular actions of Ang 
II in cardiovascular and renal tissues are almost exclusively mediated by AT1 receptors 
(Kim & Iwao, 2000). AT2 is also a G-protein-coupled receptor (Hayashida et al., 1996). 
Unlike AT1 receptors, the role of the AT2 receptor in cardiovascular and renal tissues is 
inconsistent and remains to be defined. Recent studies have suggested that the AT2 
receptor may play a counterregulatory role against the actions of Ang II mediated via the 
AT1 receptor (Horiuchi et al., 1999; Siragy et al., 1999). Recently, the AT4 receptor also 
has been identified (for review, see de Gasparo et al., 2000). 
 
The mechanism of RAS-induced hypertension has generally been attributed to the direct 
vasoconstrictor effects of Ang II and the mineralocorticoid effects of aldosterone. Ang II 
 
 
 
 
ACE  = angiotensin-converting enzyme  
CAGE  = chymostatin-sensitive angiotensin II-generating enzyme 
t-PA  = tissue plasminogen activaton 
 
Figure 1. Angiotensin II formation.  
Angiotensinogen 
Angiotensin I 
Angiotensin II 
Renin 
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• CAGE 
•
 Cathepsin G 
•
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•
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•
 Cathepsin G 
•
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REVIEW OF THE LITERATURE 
 14 
enhances sodium reabsorption and water retention through stimulation of aldosterone 
release from the adrenal gland. Ang II can also elevate blood pressure by augmenting 
noradrenaline release from sympathetic nerve endings in the vasculature (Sealey & 
Laragh, 1990), by increasing secretion of potent vasoconstrictor ET-1 and antidiuretic 
hormone vasopressin, and by reducing baroreceptor activity in the vascular smooth 
muscle, by enhancing of the Ca2+ sensitivity of the contractile apparatus of the smooth 
muscle. Ang II is also the most potent dipsogen (Sealey & Laragh, 1990), which could 
induce an increase in blood volume.  
 
Although the effectiveness of ACE inhibitors and AT1 receptor antagonists in reducing 
blood pressure in experimental models and among hypertensive patients strongly 
suggests that RAS plays an important role in the pathogenesis of essential hypertension 
(Timmermans & Smith, 1996; Gavras, 1997), the mechanisms in the development and 
maintenance of hypertension are still incompletely understood. Increased plasma RAS 
activity is not a consistent feature in hypertensive rats and patients (Paran et al., 1995). 
On the other hand, arterial wall ACE activity has been reported in rats to correlate 
positively with blood pressure (Nakata et al., 1987; Cockcroft et al., 1994), and elevated 
tissue levels of Ang II have been described in pathological conditions. The studies have 
demonstrated that local RAS is of importance in the pathogenesis of many diseases, 
including hypertension, other cardiovascular diseases, and kidney diseases, 
independent of the presence of hypertension (Egido, 1996). 
 
It is important that Ang II is not only a vasoactive hormone which regulates blood 
pressure and electrolyte homeostasis by hemodynamic effects, but it is also a growth 
factor and immunomodulator influencing cell proliferation/apoptosis and fibrosis and 
participating in inflammatory responses in a non-hemodynamic manner (for review, see 
Wolf, 1998; Luft, 2001; Ruiz-Ortega et al., 2001b). Evidence is accumulating that non-
hemodynamic effects of Ang II are essential in hypertensive end-organ damages (for 
review, see Wolf, 1998; Luft, 2001; Ruiz-Ortega et al., 2001b). 
 
Ang II is metabolized enzymatically (aminopeptidase A and N) to Ang III and Ang IV. 
Ang III stimulates the release of aldosterone secretion. In addition, Ang III is also 
involved in the feeling of thirst via AT1- and AT2- receptor stimulation. Ang IV has distinct 
actions, probably via AT4, including release of plasminogen activator inhibitor-1 from the 
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endothelium (Kerins et al., 1995; Mehta et al., 2002). In addition, Ang (1-7) is generated 
from Ang II and Ang I. The biological functions of Ang III, Ang IV, and Ang (1-7) seem to 
be less important than those of Ang II (Riordan, 1995; Wright et al., 1995; Ardaillou, 
1997).  
 
In summary, RAS plays an important role in the regulation of blood pressure. It appears 
that non-hemodynamic effects of locally formed Ang II are even more important than 
circulating Ang II in the pathogenesis of hypertension and other cardiovascular and renal 
diseases, yet the underlying mechanisms are still incompletely understood. 
 
 
2.1.1. RAS in the kidney 
 
Local renal RAS 
 
The RAS is highly active locally in the kidney. In addition to the classical pathway, in the 
kidney Ang II is also formed locally (Erdos, 1990). Ang II is formed from systemically 
delivered angiotensinogen and Ang I as well as from locally formed angiotensinogen and 
Ang I. Angiotensinogen and its mRNA are localized in the proximal tubular cells (Gomez 
et al., 1990; Ingelfinger et al., 1990; Darby & Sernia, 1995), whereas ACE is found in 
endothelial cells of the renal vasculature and in proximal tubular brush-border 
membranes (Schulz et al., 1988). AT1 receptors are present on the luminal and 
basolateral membranes of tubules and in the blood vessels (Allen et al., 1999). In 
various rat models of hypertension, including two-kidney/one-clip, Ang II infusion, 
mREN2 rat, and dTGR, total intrarenal Ang II concentration has been found to be much 
higher than circulating Ang II levels (Mullins et al., 1990; Lippoldt et al., 1996). 
 
 
Effects of Ang II on the kidney 
 
Ang II plays an important part in regulation of electrolyte homeostasis and fluid balance. 
It increases salt reabsorption both in proximal and distal tubules by increased secretion 
of aldosterone, and it regulates the glomerular filtration rate by the constriction of 
efferent arterioles, together with prostaglandin-induced vasodilation of the afferent 
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arterioles (for review, see Dzau et al., 2001). Ang II likely plays a primary role in 
progressive deterioration of renal function in patients with hypertension, diabetes, or 
primary renal diseases (for review, see Weir & Dzau, 1999). Abnormalities of the 
systemic blood pressure, and glomerular hemodynamics influenced by Ang II involve a 
number of these processes and thereby influence the rate of progression of renal 
disease (Anderson et al., 1986; Zatz et al., 1986; Norman et al., 1987; Nakamura et al., 
1995).  
 
The accumulation of extracellular matrix (e.g., collagen IV, collagen I, laminin, 
fibronectin) in the mesangial region and collapse of the glomerular capillary are critical 
factors in progressive renal dysfunction (Ikoma et al., 1991; Riser et al., 1992; Arai et al., 
1995). Ang II not only upregulates extracellular matrix production, but it also inhibits its 
degradation (Norman et al., 1987; Arai et al., 1995; Nakamura et al., 1995). In addition, 
Ang II-induced renal perivascular and peritubular inflammatory cell infiltration by blood 
pressure-independent mechanisms plays an important role in Ang II-induced glomerular 
injury and glomerulosclerosis (Kim & Iwao, 2000).  
 
Taken together, It appears that besides the regulation of blood pressure, electrolyte 
homeostasis, and fluid balance, renal Ang II-induced accumulation of extracellular matrix 
as well as the inflammatory response both also play a critical role in hypertensive 
glomerular injury and glomerulosclerosis.  
 
 
2.1.2. RAS in the heart  
 
Local cardiac RAS 
 
All components of the RAS are expressed in the heart (for review, see Bader et al., 
2001). Renin and its mRNA are present in atria, ventricles, and isolated cardiomyocytes 
of various species including humans, but the levels are very low (Dzau et al., 1987a; 
Paul et al., 1988; Endo-Mochizuki et al., 1995; Zhang et al., 1995). A recent study has 
suggested that circulating renin and prorenin are efficiently taken up by the cardiac 
circulation and may be the major source of Ang I-generating activity (van Kesteren et al., 
1997; Muller et al., 1998). Angiotensinogen is expressed in all parts of the heart and in 
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cultured cardiac myocytes and fibroblasts (Campbell & Habener, 1986; Dzau et al., 
1987b; Hellmann et al., 1988; Lindpaintner et al., 1990; Dostal et al., 1992; Sawa et al., 
1992; Sadoshima et al., 1993). ACE is produced in cardiac tissue and is mainly localized 
in fibroblasts and in the endothelium (Hirsch et al., 1990; Katwa et al., 1995). In the 
human heart, chymase may also convert Ang I to Ang II (Urata et al., 1990). AT1 and 
AT2, are about equally expressed in the heart and in isolated cardiomyocytes (Regitz-
Zagrosek et al., 1995; Booz & Baker, 1996; Rogg et al., 1996). Cardiac fibroblasts 
express only AT1 receptors under normal conditions (Crabos et al., 1994; Matsubara et 
al., 1994), but their number is increased in such conditions as heart failure ( Haywood et 
al., 1997; Ohkubo et al., 1997).  
 
 
Effects of Ang II on the heart 
 
The role of the cardiac RAS differs from that of the renal RAS, which requires Ang II for 
normal kidney development (Esther et al., 1996). Ang II is not required for the 
development or the maintenance of normal cardiac function (Holubarsch et al., 1993). 
The highly important pathogenetic effect of Ang II on cardiomyocytes is a hypertrophic 
effect (for review, see Bader et al., 2001). Ang II can also induce hyperplasia of cardiac 
fibroblasts, which thus can develop into cardiac fibrosis (Weber & Brilla, 1991). An intact 
cardiac RAS appears to be a requirement for local proliferation of fibroblasts and the 
consequent development of fibrosis (Matsusaka et al., 1999). Another important 
pathogenetic effect of Ang II on cardiomyocytes is inotropic actions on the heart (Fukuta 
et al., 1996). The inotropic effects of Ang II are apparently mediated by its influence on 
calcium homeostasis and transmembrance conductance. Ang II also has been shown to 
induce apoptosis of cardiac myocytes (Leri et al., 1998).  
 
Taken together, it seems that despite the fact that intact RAS exists in the heart, Ang II 
is not necessary for the maintenance of normal cardiac function; however, increased 
generation of cardiac Ang II plays an important role in the development of cardiac 
hypertrophy. 
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2.1.3. RAS in the vasculature 
 
Local vascular RAS 
 
The existence of renin, Ang II, ACE, and Ang II receptors in blood vessels has been well 
documented. Renin mRNA exists in the endothelial and smooth muscle cells, and renin 
can be locally synthesized in the vessel wall (Samani et al., 1987) and in cultured 
smooth muscle cells (Re et al., 1982). In addition, renin can be taken up directly from the 
circulating blood into the vessel wall (Loudon et al., 1983). Northern blot and in situ 
hybridization studies have shown that angiotensinogen mRNA exists in the arteries 
(Campbell & Habener, 1987; Cassis et al., 1988; Naftilan et al., 1991). ACE exists in 
vascular endothelial cells and vascular smooth muscle cells (VSMCs), and also exists in 
inflammatory cells (for review, see Dzau et al., 2001). Increased vascular ACE activity 
appears to be responsible for the increased vasoconstrictor response to Ang I infusion 
(Okamura et al., 1986). Ang II receptors are present in the medial VSMCs as well as in 
endothelial cells. In the adult rat, the AT1 receptor isoform is mainly expressed, while in 
fetal rats, the AT2 isoform is the predominant receptor (Viswanathan et al., 1991). AT2 
receptors may serve an important role during stages of rapid growth of the artery, and 
also have a significant function in the adult vasculature (Viswanathan et al., 1991). 
 
 
Effects of Ang II on the artery 
 
Ang II has several effects on the vascular system (Figure 2). Its main is mediated 
through its binding to AT1 receptors. One of the important effects of Ang II is its induction 
of vasoconstriction by stimulating phospholipase C and adrenergic nerves directly or 
indirectly, resulting in elevation of intracellular [Ca2+] (for review, see Palatini, 2001), 
thus increasing systemic and renal blood pressure and impairing vascular function.  
 
Ang II induces vascular remodeling including growth, apoptosis, inflammation, and 
fibrosis (for review, see Intengan & Schiffrin, 2001), mainly by increasing activation of 
protein kinase C (Smith & Timmermans, 1994; Timmermans & Smith, 1994; Brasier et 
al., 2000; Muller et al., 2001c). Ang II increases the expression of several growth factors, 
e.g., fibroblast growth factor, transforming growth factor β-1, platelet-derived growth 
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factor, and insulin-like growth factor in the vascular wall, thus resulting in hypertrophy 
and fibrosis (Dzau, 1988; Daemen et al., 1991; Gibbons, 1993; Gibbons & Dzau, 1994; 
Noble & Border, 1997). Ang II-induced VSMC growth has been seen in human vascular 
diseases and experimentally in rats (Dzau, 1988; Geisterfer et al., 1988; Daemen et al., 
1991; Gibbons, 1993; Gibbons & Dzau, 1994).  
 
 
 
 
 Figure 2. Effects of angiotensin II on an artery. 
 
 
Ang II induces vascular inflammatory responses by activating macrophages and 
increasing their ability to attach to and invade into the vascular cells (Pratt, 1996). It is 
also a potential trigger of apoptosis (Yamada et al., 1996; Tea et al., 2000). Ang II 
induces thrombosis by increasing platelet aggregation, stimulating plasminogen activator 
inhibitor-1, and promoting endothelial dysfunction and oxidative stress of blood vessels 
(Dzau et al., 1991; Griendling et al., 1993; Feener et al., 1995; Vaughan et al., 1995). All 
these Ang II-induced vascular injurious effects can be explained as being closely related 
to hypertensive end-organ damage. 
 
Taken together, Ang II-induced vasoconstriction plays a primary role in hypertension and 
vascular dysfunction. In addition, Ang II also induces vascular injuries, including vascular 
hypertrophy, apoptosis, inflammation, and fibrosis, which appear to be closely related to 
hypertensive end-organ damage. 
Angiotensin II 
Dysfunction Inflammation Apoptosis
Growth Thrombosis Fibrosis
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2.2. Arterial tone 
 
Arterial tone, one of the most important regulators of blood pressure in response to 
changes in transmural pressure (Meininger & Davis, 1992; Karibe et al., 1997), is 
determined by both the endothelium and the smooth muscle. Human essential 
hypertension and animal models of hypertension are characterized by increased 
peripheral resistance (Shepherd, 1990). Since peripheral resistance can increase as a 
result of either enhanced contractility or impaired relaxation of resistance arteries, 
functional changes in arterial smooth muscle and endothelium are important in the 
pathogenesis of hypertension and its complications (Luscher & Vanhoutte, 1986; 
Moncada et al., 1991; Cohen & Vanhoutte, 1995; Kahonen et al., 1996; Harrison, 1997; 
Kojda & Harrison, 1999; McIntyre et al., 1999).  
 
The endothelium regulates vasomotor tone, local homeostasis, and proliferation 
processes by releasing vasodilator substances (e.g., nitric oxide, prostacyclin, or 
endothelium-derived hyperpolarizing factor) and vasoconstrictor substances (e.g., 
angiotensin II, endothelin-1, prostaglandin F
2α,
prostaglandin H2, thromboxane A2, or free 
radicals) (Figure 3) in response to physiological or pathophysiological stimuli (Luscher & 
Vanhoutte, 1986; Moncada et al., 1991; Cohen & Vanhoutte, 1995; Kahonen et al., 
1996; Harrison, 1997; Kojda & Harrison, 1999; McIntyre et al., 1999).  
 
Endothelial dysfunction has been associated with several cardiovascular diseases or 
risk factors including hypertension, hypercholesterolemia, smoking, and congestive 
heart failure (Kojda & Harrison, 1999). Maintaining endothelial integrity is critical for the 
preservation of blood flow and the prevention of thrombosis. An imbalance between 
endothelium-derived constricting and relaxing factors contributes to increased peripheral 
resistance, as well as to hypertension-related end-organ damage. Endothelial 
dysfunction in hypertension may be due to impaired NO synthesis and/or inactivation of 
endothelium-derived NO by reactive oxygen species (ROS) such as superoxide, 
hydrogen peroxide, and peroxynitrite (Harrison, 1997; Kojda & Harrison, 1999; McIntyre 
et al., 1999). Recent studies support the notion that the balance between nitric oxide and 
superoxide may be even more important than the absolute levels of either alone
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Ang I  = angiotensin I  
Ang II  = angiotensin II 
AT1  = angiotensin II type I receptor 
ATP = adenosine triphosphate  
cAMP  = cyclic adenosine 3’,5’-monophosphate  
cGMP = cyclic guanosine 3’,5’-monophosphate 
COX  = cyclooxygenase  
ECE  = endothelin-converting enzyme  
EDHF = endothelium-derived hyperpolarizing factor  
ET = endothelin 
ETA  = endothelin-1 receptor A 
FP  = prostaglandin F
2α
 receptor 
 
GC  = guanylate cyclase 
IP = prostaglandin I2 receptor 
IP3 = inositol triphosphate 
L-Arg  = L-arginine 
NO  = nitric oxide  
NOS = nitric oxide synthase 
O2- = superoxide 
PC = phospholipase C  
PG  = prostaglandin 
PGI2  = prostacyclin  
PI  = phosphoinositol 
TP  = thromboxane A2-prostaglandin H2 receptor  
TXA2 = thromboxane A2
 
Figure 3. Endothelium-derived vasodilatory factors and contractile factors 
(Luscher & Vanhoutte, 1986; Moncada et al., 1991; Cohen & Vanhoutte, 
1995; Kahonen et al., 1996; Harrison, 1997; Kojda & Harrison, 1999; 
McIntyre et al., 1999). 
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(McIntyre et al., 1999). The other vasodilator products are probably of less importance 
than NO. 
 
 
2.2.1. Vascular contractile responses 
 
2.2.1.1. Angiotensin II 
 
The vascular contractile response to Ang II is mediated via AT1 receptors. The 
stimulation of AT1 receptors in VSMCs leads to the activation of phospholipase A2, C, 
and D, activation of voltage-dependent Ca2+ channels, inhibition of adenylate cyclase, 
and subsequently to an increase in intracellular [Ca2+] (de Gasparo et al., 1995; Orlov et 
al., 1993; Timmermans et al., 1993). Ang II induces VSMC contraction also by 
stimulating the sympathetic nervous system centrally and peripherally through activation 
of the presynaptic AT1 receptors (Palatini, 2001). In addition, because Ang II is a 
powerful stimulator of the potent vasoconstrictor endothelin-1 (ET-1) formation in 
VSMCs and endothelial cells (Imai et al., 1992; Crawford et al., 1994; Sung et al., 1994), 
it can further increase vascular contractile response to Ang II. 
 
 
2.2.1.2. Endothelin-1 
 
Endothelins (ETs), including ET-1, ET-2, and ET-3, are peptides that possess 
characteristically sustained vasoconstrictor properties (for review, see Schiffrin, 2001). 
The predominant member of the ET family appears to be ET-1. ET-1 is a peptide 
containing 21 amino acids; it is synthesized from larger precursor, preproendothelin, via 
the formation of proendothelin, which is cleaved to big endothelin and then catalyzed by 
endothelin-converting enzyme, and then further converted to an active peptide (for 
review, see Schiffrin, 2001). Ang II is a powerful stimulator of endothelin-1 (ET-1) 
formation in VSMCs and endothelial cells (Imai et al., 1992; Crawford et al., 1994; Sung 
et al., 1994). Moreover, production and release of ET-1 also occurs in response to many 
other stimuli, including adrenaline, cytokines, free radical, and physical factors such as 
stretch, hypoxia, and low shear stress (Kuchan & Frangos, 1993; Luscher & Noll, 1995; 
Haynes & Webb, 1998; Rothermund & Paul, 1998). Eighty percent of ET-1 is secreted 
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on the basal side of endothelial cells, resulting in concentrations within the vascular wall 
100-fold more than the levels in plasma (Wagner et al., 1992). ET-1 is one of the most 
active pressor substances discovered (for review, see Masaki, 1995). The role of ET-1 in 
the regulation of blood pressure in Ang II-induced hypertension is still unclear (Li et al., 
1996; d'Uscio et al., 1997; Rajagopalan et al., 1997; Hocher et al., 1999; Andreis et al., 
2000). However, clinically, the fact that the endothelin receptor antagonist bosentan 
significantly lowers blood pressure in patients with essential hypertension suggests that 
endothelin may contribute to elevated blood pressure in such patients (Krum et al., 
1998). Endothelin antagonists even provide a therapeutic approach beyond mere blood 
pressure lowering in hypertensive animals with cardiovascular diseases (for review, see 
Schiffrin, 2001). 
 
The vascular effects of ET-1 are mediated through two G-protein receptor subtypes, 
namely ETA and ETB.  The ETA receptor has a high affinity for ET-1, is present in smooth 
muscle cells and cardiomyocytes, and predominantly mediates contraction (Rothermund 
& Paul, 1998). Activation of ETA receptors on VSMCs increases intracellular calcium 
levels by activation of phospholipase C, leading to prolonged vasoconstriction. The ETB 
receptor is equally sensitive to the three ET isoforms, and is present both in the 
endothelial cells, where it induces the release of NO, PGI2, and perhaps other 
vasodilators―resulting in vasodilatation, and in VSMCs, where it mediates
vasoconstriction (Clozel et al., 1992; Luscher et al., 1993a; Masaki, 1998). The majority 
of endothelin receptors are of the ETA subtype and are localized in the VSMCs. 
 
Besides its direct vasocontractile properties, ET-1 can also potentiate the 
vasocontractile response to other vasoconstrictors such as NA, and it may also provoke 
the release of free radicals and COX-derived vasoconstrictor factors (Luscher et al., 
1993b; De Artinano & Gonzalez, 1999). In addition, ET-1 also has inotropic, trophic, and 
mitogenic properties, influences the homeostasis of salt and water, alters central and 
peripheral sympathetic activity, and stimulates the RAS and the sympathetic nervous 
system (Yamamoto et al., 1992; Haynes & Webb, 1998; Moreau, 1998). 
 
In short, ET-1 appears to be a predominant member of the ET family, and it has a potent 
direct or indirect vasoconstrictive property via the ETA receptor in VSMCs. Ang II is a 
powerful stimulator of ET-1 formation in the vascular wall. 
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2.2.1.3. Noradrenaline  
 
Noradrenaline (NA) is often used as a preconstricting agent in the study of endothelial-
dependent and -independent vascular relaxation responses. NA induces smooth muscle 
cell contraction by stimulating α1-adrenoceptors, which causes a rapid calcium release 
from the sarcoplasmic reticulum and prevents calcium reuptake. NA also depolarizes the 
arterial smooth muscle cells and consequently activates voltage-operated Ca2+channels 
in the plasma membrane of the smooth muscle, leading to an increased influx of Ca2+ 
(Nelson et al., 1990). The sustained contractions result from calcium influx through the 
receptor-operated calcium channels (Johns et al., 1987; Karaki & Weiss, 1988). 
 
 
2.2.1.4. Potassium chloride 
 
Any increase in extracellular potassium chloride (KCl) causes vascular contraction 
mainly by inhibition of Na+, K+-ATPase, leading to sodium leakage to the smooth muscle 
cells, which in turn causes membrane depolarization with influx of Ca2+ via the voltage-
dependent Ca2+ channels (Mulvany, 1985; Karaki & Weiss, 1988). Thus the inconsistent 
arterial contraction in response to KCl in different forms in experimental hypertension 
(Bohr & Webb, 1984) may reflect the functional changes in Na+, K+-ATPase. 
Furthermore, VSMC depolarization liberates endogenous noradrenaline from vascular 
sympathetic nerve endings, which also participates in the contractile response (Fouda et 
al., 1991).  
 
 
2.2.2. Vascular relaxation responses  
 
2.2.2.1. Endothelium-dependent vascular relaxation  
 
Acetylcholine (ACh) is the endogenous neurotransmitter at cholinergic synapses and 
neuroeffector junctions in the central and peripheral nervous system. Its actions are 
mediated through nicotinic and muscarinic cholinergic receptors, which transduce 
signals via distinct mechanisms. Acetylcholine dilates vascular beds by stimulation of 
muscarinic receptors, primarily of the M3 subtype (Bruning et al., 1994; Caulfield & 
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Birdsall, 1998), despite the lack of apparent cholinergic innervation of most arteries. The 
muscarinic receptors responsible for relaxation are located on the endothelial cells of the 
vasculature. When these receptors are stimulated, the endothelial cells release several 
endothelium-derived factors, the most prominent of these being NO, prostacyclin (PGI2), 
and the endothelium-derived hyperpolarizing factor (EDHF) (Busse R & Fleming I, 
1993). 
 
 
Nitric oxide 
 
In 1980, Furchgott and Zawadzki first reported the endothelium-derived relaxing factor. 
Later, endothelium-derived relaxing factor was recognized as NO (Ignarro et al., 1987; 
Palmer et al., 1987). NO is a small, gaseous, easily diffusible, biologically extremely 
active compound which plays a critical role in control of vascular tone. A normal 
endothelium constantly releases small amounts of NO. Extra NO is released in response 
to physiological stimuli such as increased shear stress and oxidative stress, and to 
substances such as ACh, bradykinin, histamine, thrombin, ADP, ATP, and the 
substance P.  
 
NO is constantly synthesized from the endothelial cells by NO synthases (NOS) in 
response to ACh via muscarinic-receptor stimulation (for review, see Stuehr, 1999). 
Three isoforms of NOS have been isolated: constitutive NOS, which includes endothelial 
NOS (eNOS, also called NOS III) and neuronal NOS (nNOS, also called NOS I), and 
inducible NOS (iNOS, called NOS II). eNOS plays a central role in the regulation of 
blood pressure (Ohashi et al., 1998). NO is mainly synthesized from L-arginine by 
eNOS, which is competitively inhibited by L-arginine analogues such as NG-nitro-L-
arginine methyl ester (L-NAME) (for review, see Hobbs et al., 1999). However, in the 
absence of the substrate L-arginine or the cofactor tetrahydrobiopterin, eNOS and iNOS 
may produce O2- instead of NO and thereby directly contribute to oxidative stress 
(Vasquez-Vivar et al., 1998; Xia et al., 1998; Vasquez-Vivar & Kalyanaraman, 2000).  
 
NO is unstable but can form more stable nitrosothiols, particularly with a cysteine 
residue in globin; this allows red cells to perform in the same way as endothelial cells. 
NO is inactivated by combination with the heme of hemoglobin or by oxidation to nitrite 
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and nitrate, which are excreted in the urine. Under oxidative stress, NO rapidly reacts 
with O2- to produce the toxic peroxynitrite anion (ONOO-) and other reactive nitrogen 
species. The reaction between NO and O2- occurs more rapidly than does O2- 
neutralization by superoxide dismutase (SOD) (Pryor & Squadrito, 1995). NO relaxes 
vascular smooth muscle by activation of guanylate cyclase, which leads to the increased 
production of cyclic guanosine 3’,5’-monophosphate (cGMP), and further reduces 
concentration of intracellular calcium. In vivo, NO is destroyed mainly by superoxide 
anion, and extremely reactive peroxynitrite is formed (for review, see Stuehr, 1999).  
 
In summary, NO plays a critical role in the regulation of vascular tone. Endothelial 
dysfunction in hypertension is mainly due to impaired NO synthesis and/or inactivation of 
endothelium-derived NO by ROS. It appears that the balance between nitric oxide and 
superoxide is even more important than the absolute levels of either alone. 
 
 
Prostacyclin and other prostanoids 
 
Prostacyclin (PGI2), the major vasodilatory prostanoid produced in endothelial cells, is 
released in response to shear stress, hypoxia, or to substances that stimulate NO 
formation (Gryglewski, 1995; Luscher & Noll, 1995). Prostacyclin relaxes vascular 
smooth muscle by activation of adenylate cyclase, and thus leads to increased 
production of cyclic adenosine monophosphate (cAMP). Prostacyclin is synthesized 
from arachidonic acid by COX
.
 Recently, it has been argued that in endothelium COX-2 
is mainly responsible for prostacyclin production (Kosonen et al., 1998; FitzGerald & 
Patrono, 2001). The synthesis of PGI2 is inhibited by non-steroidal anti-inflammatory 
drugs (Smith & Willis, 1971; Vane, 1971; Hawkey, 2001).  
 
In addition to the vasodilatory prostanoids, endothelial cells also produce 
vasoconstrictive prostanoids such as prostaglandin F
2α
 (PGF
2α
),
 
prostaglandin H2 
(PGH2), or thromboxane A2 (TXA2) (Matrougui et al., 1997; Kagota et al., 1999; Zhou et 
al., 1999). It has been proposed that in hypertensive rat endothelium, the production of a 
lipoxygenase can inhibit the conversion of vasoconstrictor PGH2 to PGI2, resulting in the 
accumulation of vasoconstrictor PGH2 (Cohen, 1995). Hypertension therefore seems 
also to be associated with an imbalance in the endothelial production of COX-derived 
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vasodilators and vasoconstrictors in favor of vasoconstriction. Interestingly, in contrast to 
the inhibition of NO synthase, the blockade of COX by non-steroidal anti-inflammatory 
drugs did not lower but even increased systolic blood pressure (Busse R & Fleming I, 
1993; Muscara et al., 2000). Therefore, contractile prostanoids synthesized by COX do 
not appear to participate in the development of hypertension (Taddei et al., 1997). 
 
Taken together, It appears that hypertension involves an imbalance in the endothelial 
production of vasodilatory and contractile prostanoids in favor of contractile prostanoids. 
 
 
Endothelium-derived hyperpolarizing factor (EDHF) 
 
The endothelium-mediated relaxation that remains resistant to NOS and COX inhibition 
is thought to be mediated by EDHF (Cohen & Vanhoutte, 1995). The nature of EDHF 
remains, however, unclear. It may be a cytochrome P450-derived arachidonic acid 
epoxide, e.g., 11,12 EET (Fisslthaler et al., 1999). Current data support the concept that 
the vascular relaxation elicited by EDHF is mediated by the opening of Ca2+-regulated 
K+ channels in the VSMCs (for review, see Feletou & Vanhoutte, 1999). The action of 
EDHF can be inhibited by the K+-channel blocker tetraethylammonium (TEA) or by a 
family of venom-derived peptides such as charybdotoxin and iberiotoxin, or by 
depolarization of the smooth muscle cell membrane with high potassium concentrations 
(Adeagbo & Triggle, 1993). 
 
NO has been shown to inhibit both the production and action of EDHF (Bauersachs et 
al., 1996; McCulloch et al., 1997). In physiological conditions, the contribution of EDHF 
to endothelium-dependent vasodilation is difficult to assess; EDHF-mediated dilatation 
can be observed only after inhibition of NO synthase (Bauersachs et al., 1996). 
Therefore, in the presence of impaired NO availability, a hyperpolarizing factor seems to 
act as a compensatory pathway to sustain endothelium-dependent relaxation (for 
review, see Taddei et al., 2001). 
 
 
2.2.2.2. Endothelium-independent vascular relaxation 
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NO donors, e.g., nitroglycerin, sodium nitroprusside (SNP), S-nitroso-N-acetyl-D,L-
penicillamine (SNAP), 3-morpholinosydnonimine (SIN-1), mesoionic 3-aryl substituted 
oxatriazole-5-imine derivatives (GEA compounds), share a common feature in producing 
NO-related activity when applied to biological systems. They mimic an endogenous NO 
response by generating NO or related N-oxide species in a controlled manner and thus 
offer a useful tool for pharmacological studies related to NO (for review, see Feelisch, 
1998). Clinically, NO donors are used in hypertensive emergencies and angina. They 
induce vascular smooth muscle relaxation by stimulating soluble guanylate cyclase to 
produce cGMP in the smooth muscle cells―even when endothelium is absent―or in the
presence of L-NAME, an eNOS inhibitor. NO donors also show the capacity to 
hyperpolarize vascular smooth muscle of the guinea pig or rat (Tare et al., 1990). 
Endothelium-independent relaxation by SNP is used to reflect the sensitivity of vascular 
smooth muscle to exogenous NO. 
 
 
2.2.3. Arterial tone in angiotensin II-induced hypertension  
 
In Ang II-induced hypertension, impaired endothelial function is a major change in 
vascular tone (Harrison, 1997). Ang II-induced endothelial dysfunction has been shown 
to be primarily related to increased superoxide formation within the endothelium, the 
media, and/or adventitial layer (Harrison, 1997; Kojda & Harrison, 1999; McIntyre et al., 
1999). Impaired endothelium-dependent vascular relaxation in Ang II-induced 
hypertension has been partially improved by preincubation with SOD (Rajagopalan et 
al., 1996; Wattanapitayakul et al., 2000). Reaction between NO and superoxide (O2-), 
resulting in highly active peroxynitrate (OONO-) anions, may be one of the major causes 
of impaired endothelium-dependent relaxation in Ang II-induced hypertension.  
 
Endothelium (Suzuki et al., 1995; White et al., 1996; Swei et al., 1997) and the smooth 
muscle cells (Rajagopalan et al., 1996) are the predominant sources of vascular O2- 
production in several disease states. The serum level of 8-isoprostaglandin F
2α
, a potent 
vasoconstrictor and antinatriuretic arachidonic acid metabolite, provides the index of 
oxidative stress in vivo (for review, see Romero & Reckelhoff, 1999). The O2- formation 
induced by Ang II is mainly mediated by NADPH oxidase (Laursen et al., 1997; Di Wang 
et al., 1999). Ang II induces the components of NADPH oxidase at mRNA level. Ang II 
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stimulates superoxide generation by enhancing the activity of the NADPH oxidase in 
vitro (Griendling et al., 1994) and in vivo (Rajagopalan et al., 1996).  
 
Besides NADPH oxidase, uncoupled NOS is also involved in Ang II-induced oxidative 
stress. It is clear that in both eNOS and nNOS, in the absence of the substrate L-
arginine or the cofactor tetrahydrobiopterin, heme reduction in the enzyme uncouples 
NOS, thereby producing O2- rather than NO (Vasquez-Vivar et al., 1998; Xia et al., 
1998). In atherosclerosis (Oelze et al., 2000) and diabetes (Hink et al., 2001), increased 
oxidative stress and endothelial dysfunction are associated with upregulated but 
dysfunctional uncoupled eNOS. NADPH oxidase-induced O2- by Ang II may trigger 
eNOS uncoupling, leading to impaired NO/cGMP signaling and to endothelial 
dysfunction (Mollnau et al., 2002). 
 
ROS generated by the inflammatory cells are also able to reduce the bioactivity of 
endothelium-derived NO (McIntyre et al., 1999; Romero & Reckelhoff, 1999). Ang II-
induced vascular inflammatory response is therefore one of the explanations for Ang II-
induced endothelial dysfunction. Endothelial dysfunction is an important factor in the 
relationship between inflammation and cardiovascular diseases (for review, see Blake & 
Ridker, 2001).  
 
In addition, evidence is accumulating to indicate that increased vasocontractile 
prostaglandins, e.g., prostaglandin H2, is involved in Ang II-induced impaired 
endothelium-dependent vascular relaxation by ACh (Didion et al., 2000). However, 
whether or not impaired EDHF is involved in Ang II-induced endothelial dysfunction 
remains to be clarified. Ang II induces endothelial dysfunction differently in different 
vessels, species, and under differing experimental conditions. 
 
Endothelium-independent relaxation by SNP in Ang II-induced hypertension is normally 
unaltered, indicating that the sensitivity of VSMCs to exogenous NO is not impaired 
(Arnet et al., 1999). The vascular responses to Ang II, ET-1, and NA in Ang II-induced 
hypertensive rats are inconsistent and depend on experimental conditions, and on the 
animal model and the vascular bed studied. In general, attenuated responses to Ang II 
and ET-1 have been reported in aortic arteries of mREN2 rats and Ang II-infused 
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hypertensive rats (d'Uscio et al., 1997; Arnet et al., 1999), suggesting downregulation of 
AT1 and ETA receptors expression or of their signal transduction mechanisms or of both. 
 
It seems, therefore, that endothelial dysfunction resulting predominantly from the 
reaction between NO and O2- plays an important role in Ang II-related vascular 
dysfunction. The increased O2- caused by Ang II is mainly produced by NADPH oxidase 
and by uncoupled eNOS. In addition, ROS generated by the inflammatory cells and 
increased contractile prostaglandins are also involved. However, the contractile 
responses to Ang II, ET-1, and NA are inconsistent in Ang II-induced hypertension.  
 
 
2.3. Vascular inflammatory response 
 
The Inflammatory process is a reaction of blood vessels leading to the accumulation of 
fluid and leukocytes in extravascular tissues. It has been divided into acute and 
prolonged phases. Acute inflammation is a stereotypical response to all forms of injury, 
and prolonged inflammation is due to persistent stimuli such as repeated infection or 
self-perpetuating immunological responses. Inflammation universally occurs in three 
steps: 1) increase in vascular permeability, 2) infiltration of blood cells, 3) tissue 
reconstitution and cell growth. The persistent recruitment of leukocytes is critical for the 
pathogenesis of the inflammatory response, which is considered to contribute to the 
vascular and tissue injury. 
 
 
2.3.1. Recruitment of leukocytes  
 
Leukocytes, e.g., granulocytes, monocytes/macrophages, and lymphocytes, are bone-
marrow-derived cells, which circulate in the blood in a low adhesive state before 
migrating into tissues. Leukocytes are important in the defense against invading 
microbes and participate in immune functions and wound repair. Adhesion to other cells 
and to the extracellular matrix is a fundamental feature of leukocyte physiology. An 
important prerequisite for an inflammatory response is the trafficking of leukocytes from 
the blood to the site of inflammation, including three steps; rolling, adhesion, and 
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transmigration. Many factors responsible for leukocyte adhesion and concurrent 
extravasation have been characterized, e.g., cellular adhesion molecules, cytokines, 
transcription factor NF-kB, and oxidative stress. 
 
 
2.3.1.1. Cellular adhesion molecules 
 
Leukocyte adhesion molecules play a critical role in facilitating migration of leukocytes 
from the blood to extravascular sites of inflammation. Three major families of leukocyte 
adhesion molecules exist, namely selectins, immunoglobulin superfamilies, and 
integrins. Other adhesion molecules are also involved in this process, e.g., cadherins 
and mucin-like molecules (Carlos & Harlan, 1994; Dianzani & Malavasi, 1995). 
 
The migration of leukocytes into an inflammatory site involves a series of interdependent 
and closely regulated adhesive interactions between leukocytes and the vascular 
endothelium (Ley & Tedder, 1995). The first of these interactions is mediated 
predominantly by the selectins, which are specialized in capturing free-flowing 
leukocytes from the blood (Tedder et al., 1995). The integrins are expressed in 
leukocytes and bind to the immunoglobulin superfamily, e.g., intercellular adhesion 
molecule-1 (ICAM-1) or vascular cell adhesion molecule-1 (VCAM-1), which are located 
on endothelial cells and thus mediate leukocyte firm adherence and also transduce 
signals from the extracellular matrix and the cell membrane to the inside of the cell (for 
review, see Springer, 1990). Leukocytes adhere tightly but reversibly to endothelium and 
transmigrate through the endothelium to the sites of inflammation. 
 
 
2.3.1.2. Cytokines 
 
Cytokines are peptides released from inflammatory tissue, connective tissue, and 
immune system cells; they act by autocrine and paracrine mechanisms. More than 50 
cytokines have been identified. The cytokine superfamily includes interleukins, 
chemokines, colony-stimulating factors, growth factors, interferons, and the transforming 
growth factor (TGF) and tumor necrosis factor (TNF) families. The biologic responses to 
REVIEW OF THE LITERATURE 
 32 
cytokines result from cytokine ligation on specific cytokine receptors in target cells (Rang 
et al., 1999).  
 
Cytokines are important in recruiting leukocytes to sites of inflammation. They can 
activate and stimulate the generation of leukocyte adhesion molecules in endothelial 
cells. The primary pro-inflammatory cytokines are TNF-α and interleukin (IL)-1, which 
are released from macrophages and many other cells. IL-1 synergizes with TNF-α for
many of the latter's actions, and its synthesis is stimulated by TNF-α. In addition,
chemokine IL-8 is predominantly involved in an acute inflammatory response. The 
chemokine monocyte chemoattractant protein-1 (MCP-1) is involved predominantly in 
prolonged inflammatory responses (Rang et al., 1999). 
 
 
2.3.1.3. Nuclear factor kappa-B  
 
Nuclear factor kappa-B (NF-kB), a transcription factor responsible for the regulation of 
inflammatory genes, resides as inactive and binds to the inhibitory protein I-kB in the 
cytoplasm of T lymphocytes, monocytes, macrophages, endothelial cells, and smooth 
muscle cells (Barnes & Karin, 1997). 
 
NF-kB is a pivotal transcription factor in prolonged immune responses and inflammatory 
disease (Barnes & Karin, 1997). NF-kB activation has been associated with vascular 
inflammation and cell survival (Baichwal & Baeuerle, 1997). Increased NF-kB activation 
is associated with vascular inflammation and cell survival (Baichwal & Baeuerle, 1997; 
Muller et al., 2000c). NF-kB is activated by numerous stimuli including cytokines, protein 
kinase C activators, viruses, immune stimuli, and above all, ROS. The activation of NF-
kB involves the phosphorylation and subsequent proteolytic degradation of the inhibitory 
protein I-kB by specific I-kB kinases. The free NF-kB, a heterodimer consisting of 2 
proteins, p50 and p65, passes into the nucleus, where it binds to kB sites in the 
promoter region of numerous genes involved in inflammation.  
 
 
2.3.1.4. Oxidative stress 
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In addition to the modulation of vascular tone mentioned above, oxidative stress is also 
related to cellular growth, hypertrophy, remodeling, lipid oxidation, and inflammation 
(Alexander, 1995; Kunsch & Medford, 1999; Griendling et al., 2000a). Reactive oxygen 
species (ROS) can act as intracellular signaling molecules in vascular cells controlling 
growth, survival, and apoptosis (Mervaala et al., 2000b). The specific response is 
dictated by the intracellular targets involved. The potential targets of ROS in endothelial 
and smooth muscle cells are extracellular signal-related kinases, stress-activated protein 
kinases, caspases, NF-kB, and Akt kinase.  
 
 
2.3.1.5. Nitric oxide 
 
Nitric oxide (NO) is not only a main regulator of vascular tone, but also an important 
autoregulatory inhibitor of vascular inflammation (Collins, 1993; Peng et al., 1998). It is a 
potent inhibitor of leukocyte adhesion to the microvascular endothelium and of 
thrombocyte aggregation (Gaboury et al., 1993; Kosonen et al., 1999; Kosonen et al., 
2000). The NO released by exogenous NO donors can reduce cytokine-induced 
endothelial cell activation (De Caterina et al., 1995; Khan et al., 1996), inhibit 
endothelial-leukocyte interaction (Kubes et al., 1991; Gauthier et al., 1994; Tsao et al., 
1997), and attenuate vascular inflammation (Marks et al., 1995). NO inhibition of NF-κB
occurs, in part, via the induction and nuclear translocation of the NF-κB inhibitor IκB
(Spiecker et al., 1997). NO inhibits oxidative stress in the microvasculature, through its 
ability to scavenge O2- (Miles et al., 1996). However, under oxidative stress, excess 
generation of NO contributes to the inflammatory response, in part by reacting with O2- 
to form a potent oxidant, peroxynitrite (ONOO-)/peroxynitric acid  (ONOOH) (Beckman et 
al., 1990).  
 
Endothelial-derived endogenous NO attenuates inflammatory processes (Garg & 
Hassid, 1989; Radomski et al., 1990; Moncada et al., 1991). Overexpression of eNOS 
attenuates smooth muscle proliferation and vascular inflammation in the injured rat 
carotid artery (von der et al., 1995). In eNOS- and nNOS-deficient mice, basal leukocyte 
rolling and adhesion were elevated (Lefer et al., 1999; Hickey et al., 2001), suggesting 
that eNOS and nNOS has beneficial effects in ameliorating vascular inflammatory 
responses.  
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The precise role of iNOS in the vascular inflammatory response is still poorly 
understood. Mainly, iNOS increases leukocyte recruitment by modulating leukocyte 
function but not by regulating endothelial adhesion molecules (for review, see Hickey et 
al., 2001). NO attenuates iNOS expression in macrophages, and VCAM-1 expression in 
endothelial cells and inhibits monocyte adhesion to endothelial cells (Peng et al., 1998). 
 
 
2.3.1.6. Prostanoids 
 
Eicosanoids are implicated in the control of many physiological processes and are 
among the most important mediators and modulators of the inflammatory reaction. The 
principal eicosanoids are the prostanoids, e.g., prostaglandins and thromboxanes, and 
the leukotrienes. Eicosanoids are synthesized mainly from arachidonic acid, which is 
released from cell membrane phospholipids through the action of phospholipidase A2 
and phospholipidase C (Rang et al., 1999). The free arachidonic acid is metabolized by 
several pathways―by one of two fatty acid cyclooxygenases which initiate the
biosynthesis of the prostanoids, and by various lipoxygenases which initiate the 
synthesis of the leukotrienes, and by other pathways, such as the cyp 450 catalyzed 
pathway which initiates the synthesis of other compounds, for example, 11,12-, 14,15-
epoxyeicosatetraenoic acids (EETs) (for review, see Capdevila et al., 1992). 
 
Prostanoids are local mediators of inflammation and modulators of physiological 
functions, including the maintenance of gastric mucosal integrity, the regulation of renal 
microvascular hemodynamics, renin release, and tubular electrolyte and water 
reabsorption (Moncada et al., 1973; Velo et al., 1973; Harris, 2000; Breyer & Harris, 
2001). PGI2 and TXA2 are the major prostanoids in vascular endothelium and in 
platelets, respectively (Hamberg & Samuelsson, 1974; Gryglewski, 1995). The balance 
between PGI2 and TXA2 regulates interactions between platelets and vessel wall in vivo 
(Moncada et al., 1976), whereas an imbalance between PGI2 and TXA2 may lead to 
vascular injury and thrombotic complications. 
 
Two isoforms of COX exist, namely COX-1 and COX-2. COX-1 is a constitutive isoform 
constantly expressed in most tissues under physiological conditions. COX-1-derived 
prostanoids regulate mucosal integrity of the gastrointestinal tract, arterial tone, platelet 
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aggregation, and maintenance of perfusion in the kidneys (Eberhart & DuBois, 1995; 
DuBois et al., 1998; Vane et al., 1998). The other isoform, COX-2, is not constitutively 
expressed in most tissues but can be induced in endothelial cells, fibroblasts, smooth 
muscle cells, and macrophages by proinflammatory cytokines, endotoxin, tumor 
promoters, mitogens, and hypoxia (Mitchell et al., 1995; Wu, 1995). However, COX-2 
may be expressed constitutively in some tissues, e.g., the kidneys and central nervous 
system, vascular endothelium, and the female reproductive organs. At these sites, COX-
2 activity and abundant prostanoids production is required for homeostatic and 
physiological processes (DuBois et al., 1998; Harris, 2000; Breyer & Harris, 2001; Funk, 
2001; Hinz & Brune, 2002). It still remains to be established whether COX-2 
overexpression in the vasculature is deleterious or protective. As mentioned previously, 
induction of COX-2 in macrophages and fibroblasts may contribute significantly to 
vascular inflammation, injury, and development of fibrosis, whereas COX-2 
overexpression in endothelial cells, leading to increased synthesis of vasoprotective 
prostacyclin, may represent a compensatory mechanism to defend against vascular 
injury (Wu, 1998a; FitzGerald et al., 2001). It is suggested that in the early stage of 
inflammatory response, prostanoids are mainly produced by the constitutive COX-1 
(Smith et al., 2000). Later on, the induced COX-2 is the principle contributor to the 
production of inflammatory prostanoids (DuBois et al., 1998; Herschman, 1999). The 
effects of prostanoids are mediated through stimulation of their respective receptors. 
The balance between different prostanoids is crucial for their physiological and 
pathological effects. 
 
 
2.3.2. Inflammation caused by angiotensin II 
 
Hypertension, smoking, diabetes, or elevated levels of low-density lipoprotein 
cholesterol are risk factors for vascular endothelial cell injury, and this injury initiates the 
inflammatory process (for review, see Ismail et al., 1999). Vascular injury occurring 
during inflammation is a major contributing factor in the development of organ 
dysfunction.  
 
The mechanisms of Ang II-induced vascular inflammation are not completely 
understood. Recent studies have demonstrated that Ang II may participate in the 
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inflammatory response by a direct activation of inflammatory cells or by the regulation of 
adhesion molecule and cytokine expression, via redox mechanisms and the NF-kB 
pathway, contributing to the recruitment of inflammatory cells into the lesion (for review, 
see Ruiz-Ortega et al., 2001b) (Figure 4). 
 
Ang II induces the adhesion of monocytes and neutrophils to endothelial cells (Kim et 
al., 1996; Krejcy et al., 1996) through upregulation of P-selectin, ICAM-1, and VCAM-1 
in vascular endothelial cells and through VSMCs in vivo and in vitro (Kim et al., 1996; 
Tayeh & Scicli, 1998; Pastore et al., 1999; Tummala et al., 1999). Infusion of Ang II into 
rats causes hypertension accompanied by marked monocyte infilitration as well as 
VCAM-1 and MCP-1 expression in the aorta (Capers et al., 1997; Tummala et al., 1999). 
In VSMCs and in endothelial and mononuclear cells, Ang II increases MCP-1 
(Hernandez-Presa et al., 1997; Chen et al., 1998; Ruiz-Ortega et al., 1998), the main 
chemokine for monocyte/macrophages and interleukin-8 (IL-8) (Hernandez-Presa et al., 
1998; Ortego et al., 1999), which are potent chemoattractants and activators of 
neutrophils. Ang II increases IL-6 production in vascular cells and in macrophages, and 
Ang II upregulates TNF-α and IL-6 gene expression (Han et al., 1999; Nakamura et al., 
1999). ACE inhibitor and AT1 antagonists diminish inflammatory cells, adhesion 
molecules, and also cytokine expression (Ruiz-Ortega et al., 2001d). These data show 
that Ang II activates vascular and inflammatory cells to secrete proinflammtory 
mediators that help to recruit new mononuclear cells and can thus result in additional 
inflammatory response contributing to the progression of vascular damage.  
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Ang II
Circulating
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Vascular smooth muscle cells
Ang II
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Ang II = angiotensin II 
NF-κB = nuclear factor kappa B 
O2-  = superoxide 
 
Figure 4. Mechanisms of angiotensin II-induced vascular inflammation (modified 
from Ruiz-Ortega et al., 2001b). 
 
 
Ang II-induced vascular inflammation is associated with increased formation of ROS in 
the VSMCs and myocytes (Romero & Reckelhoff, 1999; Griendling et al., 2000b). In 
VSMCs, the induction of MCP-1 and IL-6 by Ang II is dependent on the activation of 
NADPH (Chen et al., 1998; Kranzhofer et al., 1999b). Ang II increases VCAM-1 and 
MCP-1 expression by redox-related mechanisms. ROS contribute to TNF-α production
and release in part via activation of COX (Guo et al., 2001). ROS may act as signal 
transduction messengers for several important transcription factors, including NF-kB and 
activator protein-1 (Sen & Packer, 1996). 
 
NF-kB, one of the most important targets of ROS in endothelial and VSMCs, is 
associated with vascular inflammation and cell survival (Baichwal & Baeuerle, 1997). 
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Emerging data suggest the potential role of NF-kB as a mediator of the Ang II-induced 
inflammatory process. Earlier, Brasier et al (1990, 1994, 1996) showed that the 
angiotensiogen gene was transcriptionally activated during activation of NF-kB. A later 
study showed that Ang II is responsible for directing monocyte infiltration by promoting 
NF-kB activation and MCP-1 expression in a model of accelerated atherosclerosis in 
rabbits (Hernandez-Presa et al., 1997). Infusion of Ang II into normal rats increases NF-
kB activity in the vessels and kidneys (Ruiz-Ortega et al., 2000b). Ang II activates NF-kB 
in several cell types, including VSMCs, and in endothelial, glomerular, tubular, and 
mononuclear cells (Ruiz-Ortega et al., 2001a; Ruiz-Ortega et al., 2001d). Ang II 
enhances MCP-1 mRNA expression and NF-kB activity (Ruiz-Ortega et al., 2000a). 
Several reports have indicated that ACE-inhibition and AT1 receptor blockage reduce 
NF-kB activity (Sen & Packer, 1996; Ruiz-Ortega et al., 1998). The Ang II degradation 
product Ang III is also capable of activating NF-kB in renal and mononuclear cells (Ruiz-
Ortega et al., 2000a; Ruiz-Ortega et al., 2000b). Furthermore, Ang II activates NF-kB 
through both the AT1 and AT2 receptors in VSMCs (Ruiz-Ortega et al., 2000b; Wolf et 
al., 2002), implying that Ang II-mediated proinflammatory renal and cardiovascular 
effects may not be totally antagonized by the currently increased clinical use of AT1 
receptor antagonists. Possible factors of Ang II-induced inflammatory responses are 
summarized in Table 1. 
 
The interaction between Ang II and prostanoids still remains unclear. Ang II elevates the 
production of prostanoids in the kidney (Navar et al., 1996; Purdy & Arendshorst, 1999), 
which buffer the Ang II-mediated decrease in renal blood flow (Chatziantoniou & 
Arendshorst, 1992a; Chatziantoniou & Arendshorst, 1992b; Jackson & Herzer, 1993). In 
contrast, ACE inhibitors and AT1 receptor antagonists enhance the expression of COX-2 
in animals kept on a low-salt diet (Wolf et al., 1999). Ang II downregulates COX-2 
expression in macula densa (Harris et al., 2000).  
 
Ang II also induces generation of iNOS (Mervaala et al., 2000a; Park et al., 2000). 
However, the role of iNOS in the Ang II-induced inflammatory response is still not 
completely understood.  
 
 
 Table 1. Potential proinflammatory factors of angiotensin II -induced vascular inflammation. 
 
Proinflammatory factors References 
ICAM-1, VCAM-1, and P-selectin (Kim et al., 1996; Grafe et al., 1997; Mervaala et al., 1999b; Pastore et al., 1999; Tummala et al., 1999; Park et al., 2000; Piqueras et 
al., 2000; Muller et al., 2000c; Muller et al., 2001b; Theuer et al., 2002) 
α Lβ 2 and α 4β 1 integrins (Mervaala et al., 1999b) 
MCP-1 (Hernandez-Presa et al., 1997; Chen et al., 1998; Hernandez-Presa et al., 1998; Ruiz-Ortega et al., 1998; Ortego et al., 1999; Wu et 
al., 2001; Theuer et al., 2002) 
IL-1 (Wu et al., 2001) 
IL-6 (Han et al., 1999; Kranzhofer et al., 1999b; Nakamura et al., 1999; Mervaala et al., 2000a; Schieffer et al., 2000; Wu et al., 2001) 
LTA (4) (Ishizaka et al., 1999) 
TNF-α, TNF-β (Ruiz-Ortega et al., 1998; Nakamura et al., 1999; Wu et al., 2001) 
PAI-1 (Theuer et al., 2002) 
RhoA (Piqueras et al., 2000) 
NF-κB, p65 (Kranzhofer et al., 1999a; Kranzhofer et al., 1999b; Muller et al., 2000a; Park et al., 2000; Dechend et al., 2001; Ruiz-Ortega et al., 
2001a; Ruiz-Ortega et al., 2001c; Theuer et al., 2002) 
AP-1 (Park et al., 2000; Piqueras et al., 2000; Dechend et al., 2001; Haxsen et al., 2001; Ruiz-Ortega et al., 2001a)  
p-ERK (Park et al., 2000)  
IκB (Muller et al., 2001b) 
c-fos and c-jun (Muller et al., 2000a) 
ROS (Griendling et al., 1994) 
iNOS (Mervaala et al., 2000a) 
AP-1 = activator protein-1 
ICAM-1 = intracellular adhesion molecule-1  
IL = interleukin  
IκB = inhibitory protein of kappa B 
LTA (4) = leukotriene A (4) 
MCP-1 = monocyte chemoattractant protein 
NF-κB = nuclear factor kappa B  
p65 = NF-κB subunit  
PAI-1 = plasminogen activator inhibitor-1 
p-ERK   = phosphorylated extracellular signal-
regulated kinase  
Rho = small GTPase  
ROS = reactive oxygen species 
TNF-α = tumor necrosis factor-alpha 
TNF-β = necrosis factor-beta  
VCAM-1= vascular cellular adhesion molecule 
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To date, several compounds have been shown to be effective in inhibiting Ang II-
induced inflammation and vascular injury (Table 2). 
 
 
2.4. General characteristics of experimental models used in this study 
 
A double transgenic rat (dTGR) harboring human renin and human angiotensinogen 
genes was generated by Ganten and Murakami in the early 1990's (Ganten et al., 1992). 
In this model, the human RAS components do not interact with the endogenous rat RAS 
in vivo (Ganten et al., 1992). These animals are very suitable for studying human renin 
inhibitors that do not influence rat renin. Hypertension and vascular damage in this 
model are dependent on local Ang II formation (Ganten et al., 1992; Bohlender et al., 
1997). Endothelial adhesion molecule activation and perivascular leukocyte infiltration 
play a central role in the pathogenesis of Ang II-induced myocardial and renal damage in 
dTGRs (Luft et al., 1999; Mervaala et al., 1999b). Ang II induces perivascular 
inflammation in dTGRs even by blood pressure-independent mechanisms (Mervaala et 
al., 1999b). Heterozygous dTGRs die of end-organ cardiac and renal damage by week 7 
(Luft et al., 1999). 
 
The mREN2 rat, which harbors the mouse renin-2 gene, was developed in 1990 by 
Mullins et al (1990). It is the first animal model of hypertension with the advantage of a 
defined genetic basis. In this model, mouse renin converts rat angiotensinogen with a 
10-fold higher facility than does rat renin (Bohlender et al., 1998).  
 
Unlike dTGRs, the survival rate of heterozygous mREN2 rats is almost 100% at the age 
of 25 weeks. Fulminating hypertension in the presence of suppressed plasma RAS and 
high renin expression in extrarenal tissues suggests that activated extrarenal RAS may 
be responsible for the hypertensive phenotype (for review, see Lee et al., 1996). The 
recruitment and infiltration of leukocytes into the subendothelium in mREN2 rats are in 
part mediated by pressure-independent AT1 receptor pathways (Strawn et al., 1999). 
 Table 2. Some drugs protecting against Ang II-induced inflammatory response. 
 
Drugs Pharmacological class Animal model or cell type where tested Reference 
RO-65-7219  Human renin inhibitor dTGRs  (Mervaala et al., 1999b) 
Cilazapril  ACE inhibitor dTGRs (Mervaala et al., 1999b) 
Losartan  AT1 receptor antagonist SD rats infused by Ang II, human monocytic 
cells, human endothelial cells. dTGRs 
(Kranzhofer et al., 1999b;Mervaala et al., 1999a; Kiarash 
et al., 2001; Kramer et al., 2002)  
Valsartan  AT1 receptor antagonist dTGRs, Ang II infused rats, VSMCs of mouse, 
two-kidney, 1-clip rats 
(Mervaala et al., 1999a; Muller et al., 2000b; Hilgers et 
al., 2001; Wu et al., 2001; Wolf et al., 2002) 
Spironolactone  Aldosterone receptor antagonist dTGRs (Fiebeler et al., 2001) 
Bosentan  ETA/ETB receptor antagonist dTGRs (Muller et al., 2000c) 
Acetylsalicylic acid COX-1/COX-2 inhibitor dTGRs (Muller et al., 2001b) 
NS-398  COX-2 inhibitor Human cardiac fibroblasts (Scheuren et al., 2002) 
PDTC  NF-κB inhibitor dTGRs (Muller et al., 2000a; Theuer et al., 2002) 
Cyclosporin  Immunosuppressive agent dTGRs  (Mervaala et al., 2000a)  
Cerivastatin  HMG-CoA inhibitor dTGRs  
 
(Park et al., 2000; Dechend et al., 2001) 
Pioglitazone and 
rosiglitazone 
PPARγ agonist SD rats infused by Ang II (Diep et al., 2002) 
Retinoids RXR agonist VSMCs of rats (Haxsen et al., 2001) 
ACE = angiotensin-converting enzyme  
Ang II = angiotensin II  
AT1 = angiotensin II type 1 receptor  
COX = cyclooxygenase  
dTGR = double transgenic rat harboring human renin and human angiotensinogen genes  
ETA = endothelin receptor A  
ETB = endothelin receptor B  
HMG-CoA= 3-hydroxy-3-methylglutaryl-CoA  
NF-κB = nuclear factor kappa B  
PDTC = pyrrolidine dithiocarbamate  
PPARγ = peroxisome proliferator-activated receptor gamma  
RXR = retinoid X receptor 
SD = Sprague-Dawley rat  
VSMCs = vascular smooth muscle cells 
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In 1976, the Goto-Kakizaki (GK) rat, a non-obese type II diabetic rat model, was 
developed by repeated inbreeding of glucose-intolerant Wistar rats (Goto et al., 1976). It 
is an extensively studied model for type II diabetes, but not considered as a model for 
hypertension. The phenotype of GK is well characterized and exhibits several features 
typical of types II diabetes, such as impaired ontogenetic development of islet cells, 
abnormal insulin release after a glucose load, insulin resistance, a basal 
hyperinsulinemia, and abnormal glucose metabolism (Galli et al., 1999; Janssen et al., 
1999). Recent studies have demonstrated that GK rats show several structural changes 
in the kidney similar to those observed in type II diabetes patients without overt kidney 
disease. These changes include thickening of the glomerular and tubular basement 
membranes, glomerular hypertrophy, and early podocyte damage, but not 
glomerulosclerosis or interstitial fibrosis (Galli et al., 1999; Janssen et al., 1999; Riley et 
al., 1999). 
 
 
2.5. General characteristics of drugs for prolonged treatment in this 
study 
 
Angiotensin receptor antagonists 
 
Losartan and valsartan are highly selective and potent AT1 antagonists. Losartan is the 
prototype of this class of drugs, and was synthesized in 1990 (Nicholls et al., 1994). 
Since then, numerous mainly pharmacokinetically different AT1 receptor antagonists 
have been developed, and the literature about the cardiovascular effects of these 
compounds has expanded rapidly.  
 
AT1 receptor antagonists dose-dependently attenuate the pressor response to 
intravenous Ang II (Fierens et al., 1999) and reduce blood pressure in animal models of 
hypertension. They also reduce cardiac hypertrophy and improve hemodynamics in 
animal models of heart failure (Mizuno et al., 1994; Goa & Wagstaff, 1996; Hayashi et 
al., 1997; Spinale et al., 1997). They induce diuresis, increase salt excretion, reduce 
blood pressure, and reduce glomerulosclerosis in rats with prolonged renal failure
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(Mackenzie et al., 1997; Remuzzi et al., 1998). Preliminary studies suggest that AT1 
receptor antagonists are at least as effective as ACE inhibitors but with a more favorable 
adverse-effect profile. AT1 receptor antagonists reduce filtration and urinary albumin 
excretion (Gansevoort et al., 1994; Remuzzi et al., 1999). AT1 receptor antagonists 
ameliorate Ang II-induced inflammatory response and end-organ damage by blood 
pressure-independent mechanisms (Mervaala et al., 1999a; Mervaala et al., 2000a). 
 
The beneficial effect of AT1 receptor antagonists is mainly attributed to the inhibition of 
the binding of Ang II to AT1 receptor. Furthermore, any interference with the negative 
feedback control of renin release by AT1 receptor antagonists results in the 
accumulation of Ang II (Bunkenburg et al., 1991; Goldberg et al., 1993). This elevates 
the stimulation of unopposed Ang II receptors such as the AT2 receptor (Chung et al., 
1996). The stimulation of AT2 receptors has been suggested to enhance the vascular 
production of NO (Wiemer et al., 1993; Seyedi et al., 1995). In addition, Ang (1-7), which 
is generated endogenously from Ang II and Ang I, has been found to release NO and 
vasodilatory PGs from the endothelium (Jaiswal et al., 1992; Porsti et al., 1994; 
Brosnihan et al., 1996). The anti-inflammatory action of AT1 receptor antagonists may be 
mediated via the NF-kB pathway (Muller et al., 2000c).  
 
 
Cyclooxygenase inhibitors 
 
Sulindac, a non-selective COX-1/COX-2 inhibitor, and MF-tricyclic (3-(3,4-
difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone), a selective COX-2 
inhibitor, are non-steroidal anti-inflammatory agents. Sulindac is a pro-drug whose 
metabolite, sulindac sulfide, is a fairly potent inhibitor of both COX-1 and COX-2. (Myers 
et al., 2001).  
 
Unlike other COX-2 inhibitors, MF-tricyclic, a novel selective COX-2 inhibitor, does not 
affect renal blood flow in volume-depleted dogs (Black et al., 1998). Selective COX-2 
inhibitors have been shown to cause fewer gastrointestinal adverse events than do the 
previous traditional non-selective COX inhibitors (FitzGerald & Patrono, 2001). However, 
only limited information is available on the cardiovascular effects and the mechanism of 
these compounds and their interference with cardiovascular drugs at the 
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pharmacodynamic level. In fact, it has been claimed that the use of selective COX-2 
inhibitors may be associated even with increased risk for cardiovascular events 
(myocardial infarction, stroke, death) (Mukherjee et al., 2001). A recent study suggests 
that combination treatment with a COX-2 inhibitor and an AT1 receptor antagonist may 
reduce COX-2 inhibitor-induced renal adverse effects (Kistler & Ambuhl, 2001). To date, 
few studies have been published on the effect of COX inhibitors in Ang II-induced 
inflammation. The non-selective COX-1/COX-2 inhibitor acetylsalicylic acid reduces Ang 
II-induced inflammatory response in dTGRs via the NF-κB pathway (Muller et al., 2001b).  
 
The pharmacological classes and structural formulae of the drugs used for prolonged 
treatment in the present study are presented in Table 3. 
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Table 3. Pharmacological classes and structural formulas of drugs used for 
prolonged treatment. 
 
Drug   Pharmacological class   Structural formula 
 
Losartan  AT1 receptor antagonist  
 
 
 
 
 
 
Valsartan  AT1 receptor antagonist   
 
 
 
 
 
Sulindac Non-selective COX-1/COX-2 
inhibitor 
 
 
 
 
 
 
MF-tricyclic  Selective COX-2 inhibitor 
 
 
 
 
 
AT1 =angiotensin II type I receptor 
COX =cyclooxygenase 
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3. AIMS OF THE STUDY 
 
Originally, Ang II, the key effector of RAS, was considered to be a circulating vasoactive 
hormone playing a central role in the regulation of blood pressure, aldosterone 
secretion, and salt reabsorption. In the past few years, this view has been modified; Ang 
II is now considered to be a growth factor that can also regulate cellular growth and cell 
proliferation. Recently, studies support the notion that Ang II may act as an 
immunomodulator capable of inducing inflammatory responses and vascular injury even 
by non-hemodynamic mechanisms.  
 
In the present study, poorly understood mechanisms of Ang II-induced inflammation and 
vascular dysfunction were investigated, with concentration specifically on investigation of 
the following: 
 
1. The mechanisms of Ang II-induced vascular dysfunction. 
2. The involvement of increased RAS activity in the pathogenesis of hypertension, 
endothelial dysfunction, and vascular inflammation in spontaneously diabetic 
Goto-Kakizaki rats. 
3. The role of COX-1/COX-2 in the pathogenesis of Ang II-induced inflammation and 
vascular dysfunction. 
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4. MATERIALS AND METHODS 
 
4.1. Experimental animals 
 
In Study I, 40 double transgenic rats harboring human renin and human 
angiotensinogen genes (dTGRs) and 10 age-matched normotensive Sprague-Dawley 
(SD) rats (Max Delbrück Center for Molecular Medicine, Berlin, Germany) were used. 
 
Study II included 50 spontaneously diabetic Goto-Kakizaki (GK) rats and 20 age-
matched nondiabetic Wistar rats purchased from Møllegaards Breeding Centre (Ejby, 
Lille Skensved, Denmark). 
 
For Studies III and IV, 60 heterozygous transgenic rats harboring the mouse renin-2 
gene (mREN2) rats and 10 age-matched normotensive SD rats were purchased from 
Møllegaards Breeding Centre (Ejby). 
 
A summary of experimental animals and the design of the studies is presented in Table 
4.  
 
The rats were housed five animals per cage in a standard experimental animal 
laboratory (illuminated from 6.30 a.m. until 6.30 p.m.; temperature 22±1oC). They had 
free access to tap water and rat chow during the experiment. 
 
 
4.2. Drug treatments 
 
Commercially available standard rat chow served as the control diet (I-IV). In Study I, the 
AT1 receptor antagonist valsartan was dissolved in 0.5% carboxymethyl cellulose and 
administered by gavage once a day for 3 weeks; control dTGRs and SD rats received 
the same volume of vehicle.  
 Table 4. Experimental animals and experimental design of the studies. 
Study Strain and 
gender 
Age at the 
beginning (weeks) 
Experimental group and number 
of animals in each group 
Treatment 
period (weeks) 
Major measurements 
 I dTGRs 
SD rats 
Male 
4 dTGRs (n=25) 
dTGRs+valsartan (n=15) 
SD rats (n=10) 
3 SBP, vascular function in the renal artery, cardiac 
hypertrophy, proteinuria, renal XOR activity, serum 
prostaglandin F
2α
, urinary NOx 
      
 II GK rats 
Wistar rats 
Male 
8 GK rats (n=20) 
GK rats+6% NaCl (n=10) 
GK rats+valsartan (n=10) 
GK rats+6% NaCl+valsartan (n=10) 
Wistar rats (n=20) 
8 SBP, DBP, MAP, oral blood glucose test, cardiac hypertrophy 
endothelial function in the mesenteric artery, albuminuria, 
serum prostaglandin F
2α
, urinary NOx, ICAM-1 and ED1-
positive cell expression, and morphological changes in the 
kidneys 
      
 III mREN2 rats 
SD rats 
Male 
5-6 mREN2 rats (n=10) 
mREN2 rats+MF-tricyclic (n=10) 
mREN2 rats+sulindac (n=10) 
mREN2 rats+losartan (n=10) 
mREN2 rats+MF-tricyclic+losartan (n=10) 
mREN2 rats+sulindac+losartan (n=10) 
SD rats (n=10) 
8 SBP, cardiac hypertrophy, serum LDH, albuminuria, ED1-
positive cell and COX-1 and COX-2 expression, and 
morphological changes in the heart and the kidneys  
      
 IV mREN2 
SD rats 
Male 
5-6 mREN2 rats (n=10) 
mREN2 rats+MF-tricyclic (n=10) 
mREN2 rats+sulindac (n=10) 
mREN2 rats+losartan (n=10) 
SD rats (n=10) 
8 SBP, endothelial function in the aortic and renal arteries, 
urinary NOx, ETA, and ETB receptors expression in the aorta 
COX = cyclooxygenase 
dTGR = double transgenic rat harboring human renin 
and human angiotensinogen genes  
DBP = diastolic blood pressure 
ED1 = monoclonal antibody recognizing rat monocytes 
and macrophages 
ETA  = endothelin-1 receptor A 
ETB  = endothelin-1 receptor B 
GK = Goto-Kakizaki rat  
ICAM-1 = intracellular adhesion molecule-1  
LDH = serum lactate dehydrogenase 
mREN2   = mouse transgenic rat harboring the mouse 
renin-2 gene  
MAP = mean arterial blood pressure 
NOx  = nitrite plus nitrate  
SBP = systolic blood pressure  
SD = Sprague-Dawley rat   
XOR = xanthine oxidoreductase
MATERIALS AND METHODS 
 49 
In Study II-IV, compounds for oral administration were mixed directly with food. An HS 
diet (NaCl 6%) (II) was made by adding sodium chloride (Sigma-Aldrich Corp. St. 
Louis, MO, USA) to the control diet. Drug concentration in the rat chow was calculated 
based on the fact that food consumption in adult rats is usually 20-25 g/day. The route 
of administration and doses of drugs are given in Table 5. 
 
 
Table 5. Route of administration and doses of drugs.  
 
Study Drug Administration Concentration in the 
rat chow (mg/kg) 
Estimated daily 
dose (mg/kg) 
I Valsartan Gavage 0 30 
II Valsartan Mixed with diet 117  10 
III-IV Losartan Mixed with diet 467  40 
III-IV MF-tricyclic Mixed with diet 163  14 
III-IV Sulindac Mixed with diet 163  14 
 
 
4.3. Measurement of blood pressure and heart rate 
 
Tail-cuff method 
 
Systolic blood pressure and heart rate of the pretrained rats were measured with a tail-
cuff analyzer (I-IV) (Apollo-2AB, Blood Pressure Analyzer, Model 179-2AB, IITC Life 
Science, Woodland Hills, CA, USA). Before measurement, each rat was warmed at 29oC 
for 30 minutes to get detectable pulsations from its tail artery. Systolic blood pressure 
was determined by the arithmetic mean of the three consecutive results without 
disturbances of the signal. The heart rate was obtained during blood pressure 
measurement.  
 
 
Radiotelemetric method 
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In Study II, systolic blood pressure, diastolic blood pressure, and mean arterial blood 
pressure of control rats were measured by radiotelemetry also (Dataquest IV telemetry 
system, Data Sciences International, St. Paul, MN, USA), as described previously 
(Vaskonen et al., 2002). Briefly, 12-week-old rats were anesthetized with midazolam (5 
mg/kg i.p.), fentanyl (0.3 mg/kg, i.p.), and fluanisone (10 mg/kg i.p.), and the flexible 
catheter of the transmitter was surgically secured in the abdominal aorta just below the 
renal arteries, aimed against the blood flow. The transmitter was sutured to the 
abdominal wall. The rats were given buprenorfin (0.1 mg/kg s.c.) for the first two 
postoperative days. They were housed individually after the implantation and were 
allowed to stabilize for 2 weeks, unrestrained and free to move in their cages. The data 
were collected every 5 minutes for 10 seconds for each rat. The values were calculated 
with the Dataquest software.  
 
 
4.4. Metabolic studies  
 
The rats (during the last week of Study I, and every second week of Study II-IV) were 
housed individually in metabolic cages where they had free access to tap water and 
chow. Food intake and consumption of water were recorded, and urine was collected 
over 24-h periods. Urine volumes were measured and samples stored at -80 °C until the 
biochemical determinations were performed.  
 
 
4.5. Collection of blood and tissue samples 
 
At the end of the experiment, the rats were anesthetized with CO2/O2 (70/30%) (AGA, 
Riihimäki, Finland) and then decapitated. Blood samples were taken into chilled tubes 
with or without ethylenediaminetetraacetic acid (EDTA) (4.5 mM) as anticoagulant and 
centrifuged at +4oC for 15 minutes; then plasma and serum were stored at -80oC. The 
heart and kidneys were removed, washed with ice-cold saline, blotted dry, and weighed. 
The ratio of the heart weight to body weight was calculated as an index of cardiac 
hypertrophy. Tissue samples were snap-frozen in liquid nitrogen, and samples for 
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immunohistochemistry (III) and autoradiography (I, IV) in isopentane (-35oC), then all 
were stored at -80oC until assayed. Tissue samples for morphology were fixed in 4% 
buffered paraformaldehyde (I, II) or 10% formaline (III) at room temperature. 
 
 
4.6. Arterial responses 
 
The superior mesenteric artery, abdominal aorta, and renal artery were carefully 
excised and cleaned of adherent connective tissue. Three-mm sections of mesenteric 
(II) and abdominal aortic (IV), and 2 to 3-mm section of renal arteries (I, IV) were used. 
The endothelium-intact arterial rings were stretched on stainless steel hooks and 
mounted in an organ bath chamber in Krebs-Ringer buffer (pH 7.4) of the following 
composition (mM): NaCl (119.0), NaHCO3 (25.0), glucose (11.1), CaCl2.2H2O (1.6), 
KCl (4.7), KH2PO4 (1.2), MgSO4.7H2O (1.2), which was aerated with 95% O2 and 5% 
CO2. The rings were equilibrated for one hour at +37°C at a resting tension of 1.5 g. 
The force of contraction was measured with an isometric force-displacement 
transducer and registered with a polygraph (FTO3C transducer, Model 7C8 
Polygraph; Grass Instrument Co., Quincy, MA, USA).  
 
The presence of intact endothelium in the vascular preparation was confirmed by 
observing the relaxation response to 1 µM acetylcholine (ACh) in rings precontracted 
by 1 µM noradrenaline (NA) or by 0.1µM NA (renal artery in Study I). Cumulative 
concentration contractile response curves were determined for NA and endothelin-1 
(ET-1). Because of the rapid development of tachyphylaxis (Khairallah et al., 1966), 
Ang II was given only as a single concentration (0.1 µM). Cumulative relaxation 
responses to ACh and sodium nitroprusside (SNP) were examined after 
precontraction with 1 µM NA for mesenteric and aortic arteries, and 0.1µM NA for the 
renal artery. To analyze the components of endothelium-dependent vascular 
relaxation, COX and /or NOS were inhibited with diclofenac (3µM) and/or L-NAME 
(0.1mM), respectively.  
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4.7. Morphology 
 
The samples for histology were fixed with 4% buffered paraformaldehyde (I, II) or 10% 
formaline (III) for 24 hours then dehydrated and embedded in paraffin. Sections (2-3 
µm) were cut with a microtome (Leitz 1512). The sections were deparaffinized and
rehydrated before being stained with Masson's trichrome. The slides were examined 
in a blinded fashion.  
 
 
4.8. Immunohistochemistry 
 
For tissue ED1 (II, III) and ICAM-1 (II) expression, frozen kidneys (II), or formalin-fixed 
kidneys and hearts (6 µm) were processed and semiquantitative scoring was
performed as described in detail previously (Mervaala et al., 1999b). Monoclonal 
antibodies: anti- ED1 (Serotec, Oxford, England) and ICAM-1 (1A29, R&D Systems, 
Inc. Minneapolis, MN, USA) were used. The sections were counterstained with 
hematoxylin-eosin before being examined under a light microscope.  
 
 
4.9. Autoradiography  
 
Frozen kidney sections (I, II) or aorta sections (IV) (20µm thick) were cut with a 
cryostat at -17oC, thaw-mounted onto Super Frost Plus slides, dried in a desiccator 
under reduced pressure at 4oC overnight, and stored at -80oC in silica gel until further 
processing for autoradiographic studies. ACE, angiotensin receptors (AT1 and AT2), 
neutral endopeptidase (NEP), and ETA and ETB receptors were quantified by in vitro 
autoradiography as described previously (Kohzuki et al., 1991). 
 
 
4.10. Reverse transcription-polymerase chain reaction (RT-PCR) 
 
MATERIALS AND METHODS 
 53 
Frozen hearts and kidneys were used for the measurement of gene expression. Renal 
AT1 receptor mRNA (I) was measured by real time-RT-PCR (ABI's Prism 7700 
Sequence Detection System, Perkin Elmer, Corporation, Wellesley, MA, USA) according 
to the instructions of the TaqMan EZ RT-PCR TaqMan kit protocol. The following RT-
PCR primers and TaqMan-probe for GAPDH (housekeeping gene) and AT1 receptor 
were used: GAPDH forward, AAGCTGGTCATCAATGGGAAAC; GAPDH reverse, 
ACCCCATTTGATGTTAGCGG; GAPDH probe, CATCACCATCTTCCAGGAGCGCGC-
GAT, FAM (6-carboxytetrafluorescein) and TAMRA (quencher) labeled; AT1 receptor 
forward, CCATCGTCCACCCAATGAAG; AT1 receptor reverse, TGCAGGTG-
ACTTTGGCCAC; and AT1 receptor probe, FAM-TCGCCTTCGCCGCACGATG-TAMRA. 
 
COX-1 and COX-2 mRNA in the heart and kidneys (III) were also measured by RT-PCR. 
Total RNA was extracted from the kidneys and heart with Trizol (Gibco Life 
Technologies, Invitrogen Corporation, Paisley, UK) reagent, according to the 
instructions of the manufacture. After extraction and quantitation with spectrophotometry, 
a 2-µg aliquot of total RNA was reverse-transcribed to cDNA by incubation for 50 min at 
45oC in the presence of reverse trascriptase (Enhanced Avian RT-PCR kit, Sigma 
Chemical Co., USA). Subsequently, 4 µl of cDNA was subjected to PCR for the detection
of COX-1 mRNA, COX-2 mRNA, and the GAPDH mRNA. The following RT-PCR 
primers for GAPDH, COX-1, and COX-2 were used: GAPDH forward, TGGG-
GCAGCCCAGAACATCA; GAPDH reverse, GCCGCCTGCTTCACCACCTT; COX-1 
forward, CCCATCTGTTCCCCAGAGTA; COX-1 reverse, GTGAGACCCCAAGTTCC-
AAA; COX-2 forward, AGTGCCTCCCACTCCAGACT; COX-2 reverse, CACT-
GGCTTATGCCGAAAAA (Sigma Genosys, London, UK). The reaction products were 
run simultaneously on a 2% agarose gel. The intensity of the resulting bands was 
measured by a computer-based imaging analysis system (Genetools, Syngene, London, 
UK). COX-1 and COX-2 densities of COX-1 and COX-2 bands were expressed as 
relative to the density obtained for GAPDH. The intensity of the resulting bands was 
measured by a computer-based imaging analysis system (Syngene).  
 
4.11. Biochemical determinations 
 
Albuminuria 
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Urinary albumin (albuminuria) was measured by ELISA with rat albumin as a standard 
(Celltrend, GmbH, Lückenwalde, Germany). 
 
 
Serum 8-isoprostaglandin F
2α
 
 
Serum 8-isoprostaglandin F
2α
 concentration was determined by ELISA according to 
the instructions of the manufacture (Cayman Chemical, Ann Arbor, MI, USA). 
 
 
Urinary nitrate plus nitrite 
 
Urinary nitrate and nitrite (NOx) concentrations were assessed with a commercially 
available NOx colorimetric assay kit (Cayman). 
 
 
Renal xanthine oxidoreductase activity 
 
Renal xanthine oxidoreductase (XOR) activity was measured fluorometrically as 
described in detail previously (Laakso et al., 1998).  
 
 
Plasma atrial natriuretic peptide and B-type natriuretic peptide 
 
Plasma atrial natriuretic peptide and B-type natriuretic peptide levels were measured 
by radioimmunoassay as described in detail earlier (Kinnunen et al., 1993).  
 
 
Blood glucose and serum insulin 
 
Blood glucose was measured with an automatic analyzer (Reflotron, Boehringer-
Mannheim, Mannheim, Germany). Serum insulin was determined by 
radioimmunoassay (Linco Research Inc. St. Charles, MO, USA) according the 
instructions of the manufacture. 
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Serum lactate dehydrogenase 
 
Serum lactate dehydrogenase (LDH) concentration was measured enzymatically 
(United Laboratories, Helsinki, Finland). 
 
 
4.12. Compounds 
 
The following compounds were used: sodium chloride, potassium chloride (Sigma-
Aldrich Co.), acetylcholine chloride, angiotensin II acetate, NG-nitro-L-arginine methyl 
ester hydrochloride, diclofenac, oxypurinol, superoxide dismutase, noradrenaline 
bitartrate, endothelin-1, sodium nitroprusside dihydrate, carboxymethyl cellulose 
(Sigma), losartan, MF-tricyclic and sulindac (Merck & Co. Inc., Rahway, NJ, USA), 
valsartan (Novartis Ltd, Basel, Switzerland), buprenorphin (Temgesic®, Reckitt & 
Colman, Hull, UK), fentanyl-fluanisone (Hypnorm®, Janssen Pharmaceutica, Beerse, 
Belgium), and midazolam (Dormicum®, Hoffmann-La Roche, Basel, Switzerland). 
 
Compounds to be given to animals intraperitoneally were dissolved in physiological 
saline (0.9% NaCl). Compounds for in vitro vascular response studies were dissolved 
in distilled water, except oxypurinol, which was dissolved in dimethylsulfoxide (DMSO) 
(96%); the final concentration of DMSO in the buffer liquid was limited to less than 5%. 
All solutions were freshly prepared before use and protected from light. 
 
 
4.13. Statistical analysis 
 
Statistical analysis was carried out by one-way analysis of variance (ANOVA) 
supported by Tukey's (I) and LSD's (II-IV) test. ANOVA for repeated measurements 
was applied for data consisting of repeated observations at successive time-points. 
The difference was considered significant at p<0.05. The sensitivity of the artery to 
each cumulative relaxation response is presented as pD2 values, which are calculated 
as the negative log of the dose required to produce the 50% maximal response (IV)
.
 
Data are presented as means±SEM. 
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4.14. Ethics 
 
These studies were approved by the Animal Experimentation Committee of the 
University of Helsinki, Finland. 
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5. RESULTS 
5.1. Blood pressure, cardiac hypertrophy and heart rate 
 
In dTGRs, systolic blood pressure and the heart weight-to-body weight were higher 
than those of age-matched normotensive SD rats. Valsartan treatment completely 
normalized blood pressure, cardiac hypertrophy in dTGRs (I). 
 
In GK rats, systolic blood pressure measured by both tail cuff and radiotelemetry 
methods were higher than in Wistar control rats. By radiotelemetry diastolic blood 
pressure was similar between GK rats and Wistar controls (Figure 5). The heart 
weight-to-body weight ratio was higher in GK rats than in Wistar rats. Valsartan 
significantly reduced blood pressure in GK rats on a low-sodium (LS) diet. The HS diet 
for 8 weeks raised systolic blood pressure by 24 mmHg, and induced cardiac 
hypertrophy. Valsartan did not reduce blood pressure or prevent the development of 
cardiac hypertrophy in GK rats during the HS diet (II).  
 
In mREN2 rats, systolic blood pressure was markedly higher than in normotensive SD 
rats. These rats showed cardiac hypertrophy, estimated as absolute heart weights or 
heart weight-to-body weight ratios. Both the selective COX-2 inhibitor MF-tricyclic and 
the non-selective COX-1/COX-2 inhibitor sulindac further increased blood pressure 
and the absolute heart weight similarly. Losartan completely normalized blood 
pressure and prevented the development of cardiac hypertrophy, both in the presence 
and in the absence of COX inhibitors. There was a close correlation between systolic 
blood pressure and degree of cardiac hypertrophy (p<0.001, R=0.881, n=60) (III, IV). 
 
No differences appeared in the heart rate between the experimental rats and control 
rats. None of the treatments influenced the heart rate of the rats (I-IV). 
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Figure 5. 24-hour blood pressure profile of Goto-Kakizaki (GK) rats and Wistar 
rats.  Values are presented as means±SEM, n=10 in each group.  
 
 
5.2. Renal function 
 
Proteinuria (I) or albuminuria (II, III) was measured as an index of renal dysfunction in 
the present study. In dTGRs, proteinuria was 14-fold higher than in SD control rats. 
Valsartan treatment completely normalized renal function in dTGRs (I). 
 
In GK rats, albuminuria was markedly higher than in Wistar rats. The HS diet 
increased albuminuria by 350% in GK rats. Valsartan treatment did not significantly 
change albuminuria during the LS diet, but it markedly reduced high-salt-induced 
albuminuria (II).  
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In mREN2 rats, 24-hour urine volume and urinary albumin excretion rate were 
markedly higher than in SD rats. MF-tricyclic and sulindac further increased 
albuminuria in mREN2 rats, but did not significantly influence urine volume. Losartan, 
both in the absence and presence of COX inhibitors, completely prevented the 
development of albuminuria in mREN2 rats, as well as any Ang II-induced increase in 
urinary output (III).  
 
 
5.3. Arterial tone 
 
In dTGRs, the endothelium-dependent vascular relaxation by ACh was markedly 
impaired compared with that in SD controls. Preincubation of the dTGR renal arteries 
with SOD and oxypurinol markedly improved endothelium-dependent vascular 
relaxation by ACh. Endothelial-independent vascular relaxation by SNP was similar 
between dTGRs and SD rats. Contractions following a single dose of Ang II (0.1 
µmol/L) and a cumulative dose of ET-1, or NA were markedly impaired in dTGRs. 
Valsartan treatment completely normalized vascular tone in these rats (I). Detailed 
data on maximal relaxations, contractions, and PD2-values are summarized in Table 
6. 
 
 
In GK rats, endothelium-mediated vascular relaxation of noradrenaline-precontracted 
mesenteric arterial rings in response to ACh was markedly impaired compared with 
Wistar rats, but the endothelium-independent relaxations to SNP were similar in both 
strains. Preincubation of the arterial rings with the NOS inhibitor L-NAME and the 
cyclooxygenase inhibitor diclofenac abolished relaxation by ACh almost completely in 
GK rats but not in Wistar rats. The HS diet impaired vascular relaxation in response to 
ACh and also to SNP. Valsartan treatment improved endothelium-dependent vascular 
relaxation during the LS diet, but had no effect on endothelium-dependent and -
independent vascular relaxation responses during the HS diet. The improvement of 
endothelium-dependent vascular relaxation by valsartan treatment during low salt 
intake was also found after preincubation of the arterial rings with the combination of 
L-NAME and diclofenc (II). Detailed data on maximal relaxations and PD2-values are 
summarized in Table 7.  
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Table 6. Maximal relaxation and contraction responses (%) and PD2 (-log EC50) in isolated renal 
arteries from double transgenic rats harboring human renin and angiotensiongen 
genes (dTGRs), from valsartan-treated dTGRs, and from Sprague-Dawley (SD) rats, all 
aged 7 weeks.  
Values are means±s.e.; n=8 in each group; EC50 values are presented as the negative logarithm (PD2) 
of concentration of the agonist. *p<0.05 versus SD rats group,  #p<0.05 versus valsartan-treated dTGRs 
group. 
 
 
 
Table 7. Maximal relaxation responses (%) and PD2 (-log EC50) in isolated mesenteric arteries of 
16-week-old variously treated spontaneously diabetic Goto-kakizaki (GK) rats and age-
matched non-diabetic Wistar rats. 
 
 GK GK+salt GK+valsartan GK+valsartan
+salt 
Wistar rats ANOVA 
(p-value) 
Acetylcholine 
  PD2  
  
Maximal relaxation (%) 
 
Acetylcholine preincubated 
with L-NAME+diclofenac 
  PD2 
  
Maximal relaxation (%) 
 
Sodium nitroprusside 
  PD2 
  
Maximal relaxation (%) 
 
8.0±0.2 
79.4±4.6* 
 
 
 
 
 
- 
23.1±6.0#* 
 
 
8.4±0.0 
97.3±0.6 
 
7.4±0.3+#* 
62.2±5.4+#* 
 
 
 
 
 
- 
18.2±9.6#* 
 
 
7.5±0.2+#* 
92.0±1.8+#* 
 
8.0±0.2 
83.3±6.0+* 
 
 
 
 
 
- 
48.2±11.2* 
 
 
8.1±0.1 
97.8±1.0 
 
7.3±0.3+#* 
55.1±5.1+#* 
 
 
 
 
 
- 
1.2±3.2#* 
 
 
7.3±0.3+#* 
86.2±3.7+#* 
 
8.0±0.1 
97.0±1.1 
 
 
 
 
 
6.2±0.2 
67.4±4.6 
 
 
8.1±0.3 
96.2±0.7 
 
0.006 
<0.001 
 
 
 
 
 
 
<0.001 
 
 
0.003 
0.003 
Values are means ± s.e.; n=8 in each group. EC50 values are presented as the negative logarithm (PD2) 
of concentration of the agonist. *p<0.05 vs. Wistar rats group,  p+<0.05 vs. GK controls group, p#<0.05 vs. 
valsartan-treated GK rats group. 
 
 
dTGRs dTGRs+Valsartan SD rats ANOVA (p-value) 
Relaxation responses to: 
    
Acetylcholine     
         PD2  7.61±0.19 7.38±0.10 <0.001 
         Maximal relaxation (%) 43.07±13.43*# 93.92±2.01 93.46±2.16 <0.001 
Sodium nitroprusside     
         PD2 7.85±0.26# 9.04±0.16 8.47±0.28 0.005 
         Maximal relaxation (%) 91.38±2.38*# 98.24±0.37 97.90±0.49 0.003 
Contraction responses to: 
    
Endothelin-1     
         PD2 8.62±0.18 8.83±0.11 8.59±0.26 0.835 
         Maximal contraction (g) 0.81±0.33*# 1.86±0.16 2.00±0.17 0.006 
Noradrenaline     
         PD2 6.40±0.13* 7.12±0.17 7.28±0.11 0.018 
         Maximal contraction (g) 1.28±0.13*# 1.87±0.24 1.93±0.23 0.021 
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In mREN2 rats, the endothelium-dependent vascular relaxation by ACh and 
endothelium-independent vascular relaxation by SNP were markedly impaired in the 
aorta but not in the renal arteries when compared to SD controls. The endothelium-
dependent relaxation by ACh was improved by preincubation of the aortic rings with 
diclofenac, and was completely abolished by preincubation with either L-NAME alone or 
the combination of diclofenac and L-NAME. The tendency toward contractile responses 
with the highest ACh concentration (10µM) disappeared totally in the presence of
diclofenac. Both in the aorta and renal arteries, the contractions caused by a single dose 
of Ang II (0.1 µmol/L) were slightly more pronounced in mREN2 rats than in SD controls.
The contractile responses to ET-1 were attenuated in the aorta, but not in the renal 
arteries. No differences occurred in contractile response to NA in either strain. Losartan 
treatment of mREN2 rats completely normalized endothelium-dependent vascular 
relaxation by ACh and endothelium-independent vascular relaxation by SNP. In 
losartan-treated mREN2 rats, 20% relaxation by ACh remained in the presence of the 
combination of diclofenac and L-NAME, indicating that losartan improves endothelial 
function in mREN2 rats through the EDHF pathway. In addition, losartan treatment 
attenuated Ang II-induced contractions both in the aorta and in the renal arteries, and 
normalized ET-1-induced contractions in the aorta. Neither In vivo treatment with MF-
tricyclic nor sulindac showed any clearly protective effect on vascular tone in mREN2 
rats (IV). 
 
 
5.4. Inflammation 
 
Tissue morphology 
 
In dTGRs, the media-to-lumen ratio of mesenteric arteries was slightly increased 
compared to that of SD rats (0.20±0.04 versus 0.14±0.09, p<0.05) (I). 
 
In GK rats, the kidneys on the HS diet showed some mesangial thickening and slight 
thickening of the media of the afferent arteriols, but with no clear signs of 
glomerulosclerosis or interstitial fibrosis (II).  
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In mREN2 rats, the myocardium showed severe histopathological changes. In the 
larger epicardial arteries appeared notable adventitial fibrosis and medial hypertrophy. 
There was an increase in inflammatory cells in the perivascular area. Smaller, mostly 
intramuscular arteries were even more severely damaged, and showed concentric 
hypertrophy occluding the vessel lumens. Neither MF-tricyclic nor sulindac had any 
clearly beneficial or detrimental effects on cardiac morphology. In contrast, losartan 
completely prevented the Ang II-induced morphological changes in mREN2 rats, both 
in the presence and in the absence of COX inhibitors (III).  
 
In mREN2 rats, the kidneys showed focal glomeruloscerosis with mesangial 
expansion, and apparent tubular atrophy with mild peritubular/interstitial fibrosis. The 
mid-sized arteries showed notable adventitial and medial thickening, whereas the 
smaller arteries also had intimal hyperplasia, leading to narrowing of the luminal 
space. Inflammatory cells appeared in periarterial and peritubular areas. Neither MF-
tricyclic nor sulindac was able to prevent Ang II-induced changes in renal morphology. 
In contrast, some samples of the selective COX-2 or non-selective COX-1/COX-2 
inhibitor groups showed necrosis of the tubular epithelium. Renal morphology in 
mREN2 rats treated with losartan was indistinguishable from that of SD rats (III).  
 
 
Leukocyte accumulation and adhesion molecule expression 
 
GK rats during the LS diet already had significant monocyte/macrophage infiltration 
(ED1-positive cells) in the renal perivascular space and increased expression of ICAM-
1 in the interstitium, intima, and adventitia of the small renal vessels. The HS diet 
aggravated their inflammatory response. Valsartan treatment reduced the number of 
ED1-positive cells and ICAM-1 expression during both LS and HS diets (II). 
 
In mREN2 rats, ED1-positive cells appeared both in the heart and kidneys. Neither 
MF-tricyclic nor sulindac ameliorated the inflammatory response in these mREN2 rats, 
and losartan completely prevented leukocyte infiltration (III). 
 
 
COX expression 
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In mREN2 and SD rats, only minimal COX-2 protein expression appeared in 
endothelial cells in the heart (data not shown). Weak COX-2 immunopositive staining 
was also found in the cortex and medullary interstitial cells. Renal COX-2 expression 
was clearly lower in mREN2 rats than in SD rats (III). 
 
COX-2 mRNA expression in the heart and kidneys was also lower compared that into 
SD rats. MF-tricyclic, sulindac, and losartan significantly increased myocardial and 
renal COX-2 mRNA expression in mREN2 rats. No difference existed in COX-1 mRNA 
expression in the heart or kidneys between mREN2 and SD rats. Sulindac enhanced 
COX-1 mRNA expression, but not MF-tricyclic. Losartan did not influence COX-1 gene 
expression when given alone or in combination with COX inhibitors (III). 
 
 
Excretion of NO metabolites  
 
Urinary nitrate plus nitrite (NOx), the main NO metabolites, was measured in the 
present study. In dTGRs, urinary NOx excretion was reduced by 85% compared to 
SD control rats. Valsartan treatment markedly improved urinary NOx excretion in 
these rats (I). 
 
In GK rats, urinary NOx excretion was similar to that in Wistar controls, but was 
markedly increased during the HS diet. Increased NOx excretion in GK rats during the 
HS diet was normalized by prolonged treatment with valsartan (II). 
 
In mREN2 rats, urinary NOx excretion was lower than in SD controls, and was 
completely normalized by losartan treatment. In contrast, both MF-tricyclic and 
sulindac slightly reduced (p<0.05) or tended to reduce their urinary NOx excretion (IV). 
 
 
5.5. Oxidative stress 
 
In the present study, serum 8-isoprostaglandin F
2α
 level and renal xanthine 
oxidoreductase activity, the indirect markers of oxidative stress in vivo (for review, see 
Romero & Reckelhoff, 1999), were measured. 
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Serum 8-isoprostaglandin F
2α 
 
In dTGRs, serum 8-isoprostaglandin F
2α
 levels were 100% higher than in SD control 
rats. Valsartan treatment completely normalized serum 8-isoprostaglandin F
2α
 levels 
(I). 
 
In GK rats, serum 8-isoprostaglandin F
2α
 levels tended to be higher than in Wistar 
rats, but not significantly. The HS diet raised serum 8-isoprostaglandin F
2α
 levels by 
400% in GK rats; this was prevented by prolonged treatment with valsartan (II).  
 
 
Renal xanthine oxidoreductase activity 
 
In dTGRs, the activity of XOR in the kidney was 40% higher than in SD control rats. 
Vasartan treatment completely normalized their renal XOR activity (I). 
 
 
5.6. Blood glucose and serum insulin 
 
In GK rats, blood glucose and serum insulin levels were higher than in Wistar rats, but 
were not markedly influenced by the HS diet or by valsartan treatment (II). 
 
 
5.7. Plasma atrial natriuretic peptide and B-type natriuretic peptide 
 
In GK rats, plasma atrial natriuretic peptide and B-type natriuretic peptide 
concentrations were similar to those in Wistar controls. Neither the HS diet nor 
valsartan treatment affected plasma atrial natriuretic peptide concentrations. Plasma 
B-type natriuretic peptide levels were elevated by the HS diet both in the presence 
and in the absence of valsartan treatment (II). 
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5.8. Serum lactate dehydrogenase 
 
In mREN2 rats, serum LDH concentrations were similar to those in SD controls, and 
no drugs used had any influence on this (III). 
 
 
5.9. Angiotensin receptors, angiotensin-converting enzyme, neutral endo-
peptidase, and endothelin receptors expression 
 
In dTGRs, renal AT1 mRNA expression was markedly lower than  in SD rats. Valsartan 
treatment raised renal AT1 mRNA expression to the levels found in SD rats. In 
dTGRs, AT1 and AT2 receptor expression in the cortex and medulla were also 
markedly reduced, whereas ACE expression remained unchanged. Valsartan slightly 
elevated cortical AT1 receptor expression but did not influence AT1 receptor 
expression in the medulla; similarly, AT2 receptor and ACE expression were both 
unchanged (I). 
 
In GK rats, AT1 receptor expression in the medulla was lower than in Wistar rats, 
whereas cortical AT1 receptor expression, medullary and cortical AT2 receptor 
expression, and renal ACE and NEP expressions were unchanged. The HS diet did 
not influence renal AT1, AT2, ACE, or NEP expression. In valsartan-treated GK rats, 
the cortical and medullary AT1 receptor expression were lower in the presence and in 
the absence of the HS diet (II).  
 
In mREN2 rats, ETA and ETB receptor expressions in the aorta did not differ from 
those in SD rats. None of the drugs significantly influenced ETA and ETB receptor 
expressions. In the aorta, ETA receptor expression was 7 to 20 times as high as ETB 
receptor expression (IV). 
 
5.10. Body weight, food intake, and drug dosages 
 
In Studies III and IV, final body weight in untreated mREN2 and SD rats (412±8 vs. 
392±14 g, p=0.27) was similar. At the end of the experimental period body weight of 
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sulindac-treated (455±17 g), losartan-treated (452±19 g), and MF-tricyclic+losartan-
treated (457±15 g) rats were slightly, but significantly higher than of untreated mREN2 
rats (p<0.05). No difference existed between the treatment groups in the 24-hour food 
intake at 2, 4, 6, and 8 weeks. 
 
During the 8-week experimental period, the daily dosage of selective COX-2 inhibitor 
MF-tricyclic varied from 22 to 9 mg/kg, that of non-selective COX-1/COX-2 inhibitor 
sulindac from 25 to 9 mg/kg, and that of losartan from 67 to 27 mg/kg during the 8 
weeks’ experiment (III, IV). 
 
The main findings in the animals and the effects of compounds in corresponding 
animals are summarized in Table 8. 
 Table 8. Main findings in the rats and effects of prolonged treatment with different compounds in corresponding animals (I-
IV). 
Study Strain Treatment SBP Cardiac 
hypertrophy 
Proteinuria NOx 
 
Serum 8-
isoprostaglandin F2α 
Renal XOR activity 
I SD Vehicle  − − − − − − 
I dTGR Vehicle  ↑ a ↑ a  ↑ a       ↓ a ↑ a ↑ a 
I dTGR Valsartan ↓ b ↓ b  ↓ b       ↑ b ↓ b ↓ b 
 
Study Strain Treatment SBP Cardiac 
hypertrophy 
Albuminuria NOx Serum 8-
isoprostaglandin F
2α
 
Renal ED1-
positive cells 
Renal 
ICAM-1 
II Wistar Vehicle  − − − − − − − 
II GK Vehicle  ↑ c ↑ c ↑ c ↔ c ↔ c ↑ c ↑ c 
II GK High salt  ↑ d ↑ d ↑ d ↑ d ↑ d ↑ d ↑ d 
II GK Valsartan ↓ d ↔ d         ↔d ↔ d ↔ d ↓ d ↓ d 
II GK High salt+valsartan ↑ d ↑ d ↑ d, ↓ # ↔ d, ↓ # ↔ d, ↓ # ↓ d, ↓ # ↓ d, ↓ # 
 
Study Strain Treatment SBP Cardiac 
hypertrophy 
Albuminuria NOx Cardiac ED1-postive 
cells 
Renal ED1-positive cells 
III, IV SD Vehicle − − − − − − 
III, IV mREN2 Vehicle ↑ e ↑ e ↑ e ↓ e ↑ e ↑ e 
III, IV mREN2 MF-tricyclic ↑ g ↑ g ↑ g ↓ g ↔ g ↔ g 
III, IV mREN2 Sulindac ↑ g ↑ g ↑ g ↔ g ↔ g ↔ g 
III, IV mREN2 Losartan ↓ g ↓ g ↓ g ↑ g ↓ g ↓ g 
III, IV mREN2 MF-
tricyclic+losartan 
 ↓
g * 
 ↓
g *
  ↓
g *
   ↓
g *
  ↓
g *
 
III, IV mREN2 Sulindac+losartan  ↓ g *  ↓ g *  ↓ g *   ↓ g *  ↓ g * 
 − normal; ↑ increased; ↓ decreased; ↔ no changes; a compared to SD rats in Study I (I); b compared to untreated dTGRs (I); c compared to Wistar rats (II); d 
compared to untreated GK rats (II); # compared to GK rats with high-sodium diet (II); e compared to SD rats in Studies III and IV; g compared to untreated 
mREN2 rats (III-IV); * compared to MF-tricyclic- and sulindac-treated mREN2 rats. 
 
dTGR = double transgenic rat harboring human renin and human angiotensinogen 
genes 
ED1 = monoclonal antibody recognizing rat monocytes and macrophages 
GK = Goto-Kakizaki rat 
ICAM-1   = intracellular adhesion molecule-1 
mREN2  = mouse transgenic rat harboring the mouse renin-2 gene 
NOx  = nitrite plus nitrate 
SBP = systolic blood pressure 
SD = Sprague-Dawley rat 
XOR = xanthine oxidoreductase
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6. DISCUSSION 
 
RAS plays a central role in the regulation of blood pressure, sodium excretion, and 
aldosterone secretion. Ang II is a key effector of RAS, and recent studies have 
demonstrated that Ang II-induced inflammation and vascular injury are involved in the 
pathogenesis of Ang II-induced hypertension and other cardiovascular diseases. The 
exact mechanisms, however, still remain unclear. In the present study, the role of 
oxidative stress and COX isoenzymes in the Ang II-induced inflammatory response 
and vascular dysfunction were evaluated by the use of two transgenic models with 
increased local RAS: dTGRs and mREN2 rats, and spontanously diabetic GK rats.  
 
 
6.1. Methodology 
 
Rat strains 
 
The three models chosen, i.e., the dTGR, and the mREN2 and GK rat, were especially 
suitable for answering the questions concerning the mechanisms and prevention of 
Ang II-induced vascular injury and inflammatory response. In dTGRs, the rat and 
human RAS do not interact, so the pathogenesis in this rat is the result of the 
overexpression of the human RAS (Muller et al., 2000a; Muller et al., 2000b), thus, the 
dTGR can be regarded as a good animal model for studying the mechanisms of Ang 
II-induced pathogenesis and the effect of ACE inhibitors and AT1 antagonists in man. 
As compared to that of dTGRs, the pathogenesis of heterozygous mREN2 rats is 
moderate, and the survival rate of heterozygous mREN2 rats is also much longer. 
Therefore, the effects of 3 weeks’ treatment of dTGRs and 8 weeks’ treatment of 
mREN2 rats could be determined without loss of animals.  
 
In the present study, that spontaneously diabetic GK rats are salt- sensitive and show 
several structural changes in the kidney similar to those observed in type II diabetic 
patients, implies that these rats may be a good animal model for studying the 
pathogenesis of type II diabetes in man. 
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Blood pressure measurements 
 
In the present study, blood pressure was measured by the tail cuff method. In Study II, 
blood pressure was also measured by the radiotelemetry method. Blood pressure 
measured by the tail cuff method has shown a good correlation with direct recordings 
by using intra-arterial catheters (Bunag & Butterfield, 1982). The advantages of this 
method are its low cost and simplicity. The limitations, on the other hand, are 
overestimation of blood pressure by stressful stimuli from the environment, e.g., 
people, noise, high temperatures, tail-cuffs, and holders. Stress-induced influences 
can be minimized by pre-training the animals, and by having the same person 
regularly perform the measurements in a peaceful environment.  
 
The radiotelemetry method offers the possibility for providing accurate, reliable, and 
continuous recordings in unrestrained, untethered animals for a relatively long time-
period. The main limitations of the method are the process of telemeter setting and the 
expensive devices operation for telemeter setting and the expensive device. 
 
In the present study, systolic blood pressure measured by the tail cuff and 
radiotelemetry method in GK rats was similar. In accordance with our previous pilot 
study in diabetic Zucker rats (data not shown), the present results indicate that the 
telemetric and tail cuff values are also comparable in GK rats. 
 
 
Arterial ring preparations 
 
The major complications of hypertension result from injury to relatively large arteries 
(Safar et al., 1998). Regional differences in the vascular effects of increased RAS have 
also been described in spontaneously hypertensive rats (Clozel et al., 1991). In the 
present study, we used the superior mesenteric artery, renal artery, and aorta in 
different experiments. The mesenteric artery served as a model of a resistance artery 
and is suitable for the experimental setting, which required stable precontractions and 
reproducible relaxation responses. The aorta does not contribute to peripheral 
vascular resistance, but may serve as a model of conduit arteries, which are most 
prone to vascular diseases and responsible for the clinical consequences of 
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hypertension. Renal failure is a common complication of hypertension. Functional 
changes in renal arteries may play an important role in the regulation of renal 
hemodynamics and renal function. It is noteworthy that Ang II may affect arterial 
function differently in different parts of the vasculature. 
 
 
Dosage selection of COX inhibitors 
 
Dosage choices for the selective COX-2 inhibitor MF-tricyclic and non-selective COX-
1/COX-2 inhibitor sulindac were based on in vivo studies performed in mice (Oshima 
et al., 1996), and male SD rats (Buttar et al., 2002). Using a mouse model of human 
familial adenomatous polyposis, Oshima et al. (1996) reported that treating the mice 
with MF-tricyclic suppresses polyp formation in a dose-dependent manner. MF-
tricyclic, when given at daily dosages of 14 mg/kg and 3.5 mg/kg (mixed in the chow), 
reduced the number of polyps by 62% and 50%, respectively. In contrast, sulindac (12 
mg/kg mixed in chow) did not influence polyp formation. In that experiment, the drug 
concentration in mice receiving MF-tricyclic at a daily dosage of 14 mg/kg was 0.45 
µg/ml (corresponding approximately to 1.3 µmol/l), and that of sulindac sulfide, the
active form of sulindac, in mice receiving sulindac (12 mg/kg) 0.54 µg/ml
(corresponding approximately to 1-2 µmol/l). 
 
Buttar et al. (2002) reported recently that MF-tricyclic, when given orally to SD rats for 
28 weeks at a daily dosage of 10 mg/kg (mixed in the chow), inhibits inflammation, 
COX-2 activity, and the development of adenocarcinoma. In that study, high-dose 
sulindac (30 mg/kg mixed in the chow) also exerted a pronounced anti-inflammatory 
effect and protected against development of adenocarcinoma. The serum drug 
concentration in rats receiving MF-tricyclic at a daily dose of 10 mg/kg was about 0.8 
µg/ml, which, according to the authors, is approximately double the amount that can
be achieved with 25 mg of rofecoxib (a MF-tricyclic derivative) in humans.   
 
Studies in male SD rats have revealed that MF-tricyclic exerts the following in vivo 
activities after drug administration: rat paw edema inhibitory dose (ID50): 2.8 mg/kg, 
antipyretic ID50: 0.22 mg/kg, rat paw hyperalgesia ID50: 1.3 mg/kg, adjuvant arthritis:  
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about 1 mg/kg. The bioavailability of this drug is high (Pauline Luk, Merck Frost 
Canada, personal communication). 
 
Cell culture studies using recombinant human COX-1 and COX-2 proteins have 
revealed that MF-tricyclic inhibits COX-2 at nanomolar concentration (IC50: 16.4 
nmol/l) and COX-1 at high micromolar concentration (IC50 > 50 000 nmol/l) (Oshima et 
al., 1996). In contrast, sulindac sulfide inhibits both COX-1 and COX-2 at nanomolar 
concentration (IC50 for COX-1 47.9 nmol/l; IC50 for COX-2 1.2 nmol/l) (Oshima et al., 
1996). In human whole blood assays, MF-tricyclic inhibits COX-2 at low micromolar 
concentration (IC50: 0.82 µmol/l), and COX-1 at high micromolar concentration (IC50: 
35 µmol/l) (Pauline Luk, Merck Frost Canada, personal communication). 
 
In the present study, food consumption in mREN2 rats was recorded every second 
week by using metabolic cages, and the average drug dosages of MF-tricyclic and 
sulindac from the metabolic data were calculated. In our 8-week experiment, the daily 
dosage of MF-tricyclic varied from 22 to 9 mg/kg, and that of sulindac from 25 to 9 
mg/kg. Taking into consideration the data from these in vivo and in vitro studies, it is 
likely that MF tricyclic, as well as sulindac, produced COX inhibition also in our 
experiment. The drug-induced increases in blood pressure and the 24-hour 
albuminuria, as well as the drug-induced changes in renal COX mRNA and protein 
expressions, also support this notion. 
 
 
6.2. Increased RAS activity genetically and vascular dysfunction  
 
In the present study, as an indication of endothelial dysfunction, endothelium-
dependent relaxation responses to ACh were impaired in dTGRs and mREN2 rats (I, 
IV). However, the endothelium-independent relaxation responses to SNP and the 
vascular contractile responses to Ang II, ET-1, and NA were inconsistent. These 
results suggest that Ang II-induced vascular dysfunction is mainly due to endothelial 
dysfunction.  
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Ang II, when infused into normotensive rats, induces pronounced endothelial 
dysfunction (Rajagopalan et al., 1996; Wattanapitayakul et al., 2000). Ang II-induced 
endothelial dysfunction is secondary to increased superoxide formation within the 
endothelium, the media, and/or adventitial layer (Harrison, 1997; Kojda & Harrison, 
1999; McIntyre et al., 1999). Endothelial dysfunction in Ang II-infused rats can be 
corrected by SOD and by AT1 receptor blockade (Rajagopalan et al., 1996). Even a 
subpressor dose of Ang II causes oxidative stress, as measured by the production of 
serum 8-isoprostaglandin F
2α
 level, a noncyclooxygenase-produced metabolite of 
arachidonic acid (Romero & Reckelhoff, 1999). In agreement with this, the present 
study showed that the serum 8-isoprostaglandin F
2α
 level was about 100% higher in 
untreated dTGRs, and that preincubation of the renal arteries with SOD normalized 
ACh-mediated, endothelium-dependent vascular relaxation completely. Furthermore, 
urinary NOx, a marker of total body NO generation, was decreased in dTGRs and 
mREN2 rats. These support the previous finding that Ang II selectively reduces 
vascular NO bioactivity (Wattanapitayakul et al., 2000) by increased oxidative stress 
(Romero & Reckelhoff, 1999; Haas et al., 1999). However, whether or not endothelial 
dysfunction in dTGRs and mREN2 rats is due to the direct effects of Ang II on 
endothelial cells or whether Ang II-induced hypertension is capable of impairing 
endothelial function indirectly, or both, remains to be determined.  
 
Previous studies by us and others have shown that spontaneously hypertensive rats 
and Dahl salt-sensitive rats have higher XOR activities in the kidney and other tissues 
than Wistar controls (Suzuki et al., 1998; Laakso et al., 1998), and that prolonged 
inhibition of NOS by L-NAME induces renal XOR in spontaneously hypertensive rats 
(Laakso et al., 1999). The increased renal XOR activity in dTGRs speaks for the 
involvement of XOR in the renal pathogenesis induced by Ang II. The moderate 
improvement, however, of the endothelium-dependent relaxation response by 
preincubation of the vascular rings with the XOR inhibitor oxypurinol in dTGRs 
suggests only partial involvement of XOR in ROS generation. It is therefore very likely 
that, compared to XOR, other enzyme systems capable of producing ROS (e.g., 
NADH/NADPH oxidase and uncoupled endothelial NO synthase) play a more 
important role in the onset of Ang II-induced vascular dysfunction in dTGRs (Fukui et 
al., 1997; Laursen et al., 1997). 
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In the present study, prolonged treatment with AT1 receptor antagonists effectively 
normalized endothelium-dependent vascular relaxation responses to ACh and 
improved endothelial-independent vascular relaxation responses to SNP both in 
dTGRs and mREN2 rats, indicating that Ang II impairs endothelial function and 
sensitivity of VSMCs to NO via stimulation of the AT1 receptor. 
 
Ang II induces a vascular contractile response via the AT1 receptor in VSMCs. In 
dTGRs, the contractile response to Ang II was less prominent than in SD rats. 
Previously we have demonstrated that Ang II concentrations in the plasma and kidney 
are 4- to 5-fold higher in dTGRs than in SD rats (Mervaala et al., 2000b). In the 
present study, AT1 receptor protein expression and AT1 mRNA were both lower in 
dTGR kidneys. The present findings clearly indicate that high circulating Ang II and 
tissue Ang II concentrations induce agonist-dependent AT1 receptor downregulation in 
dTGRs. Furthermore, vascular responses to ET-1 and NA were also attenuated and 
normalized by valsartan treatment in dTGRs, suggesting that down-regulated ETA 
receptors and α-adrenoceptors may also be involved in Ang II-induced vascular 
dysfunction in dTGRs.  
 
In contrast to dTGRs, vascular contractile responses to Ang II were slightly more 
prominent in aortic and renal arteries in mREN2 rats than in SD rats. Noll et al (1997) 
have also demonstrated an enhanced contractile response to Ang II in the mesenteric 
artery of mREN2 rats. These results indicate that high tissue Ang II concentrations do 
not induce agonist-dependent down-regulation of the AT1 receptor in mREN rats. In 
the present study, the vascular contractile responses to ET-1 in mREN2 rats were 
attenuated in the aorta, but not in the renal arteries. However, ETA and ETB receptors 
were not down-regulated in mREN2 rats. In contrast to our findings in dTGRs, the 
vascular contractile responses to NA in mREN2 rats were not attenuated, neither in 
the aorta nor in the renal artery, suggesting that hypertension in mREN2 rats is not 
associated with agonist-dependent down-regulation of the α-adrenoceptors. The AT1 
receptor antagonist valsartan completely normalized vascular responses in mREN2 
rats. 
 
In summary, endothelial dysfunction is the major change in Ang II-induced vascular 
dysfunction which is mainly related to Ang II-induced oxidative stress. Increased XOR 
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activity is partially involved in the generation of O2- by Ang II. The vascular contractile 
response to Ang II, ET-1, and NA depends upon differences in animal species and 
vasculature. AT1 receptor antagonists are able to normalize Ang II-induced oxidative 
stress and vascular dysfunction completely, indicating Ang II-induced vascular 
dysfunction via stimulation of the AT1 receptor. 
 
 
6.3. Increased RAS activity in spontaneously diabetic Goto-Kakizaki 
rats 
 
In the present study, spontaneously diabetic GK rats showed higher blood glucose 
and serum insulin levels, and impaired blood glucose tolerance, than did Wistar 
controls. GK rats were also moderately hypertensive and showed markedly impaired 
endothelial function, pronounced perivascular monocyte/macrophage infiltration, and 
overexpression of adhesion molecules in the kidneys.  
 
Long-term treatment with the AT1 receptor antagonist valsartan normalized blood 
pressure and improved endothelial dysfunction and perivascular inflammatory 
response in GK rats during the LS diet, indicating the involvement of increased RAS 
activity. The improvement of endothelium-dependent vascular relaxation by valsartan 
treatment also occurred when production of NO and prostacyclin were blocked, 
suggesting that endothelial dysfunction in GK rats may be attributed, at least in part, to 
reduced relaxation via EDHF in the vascular smooth muscle (Cohen & Vanhoutte, 
1995). However, the improvement in endothelium-dependent vascular relaxation by 
valsartan may also have been, at least in part, due to stimulation of the AT2 receptor, 
leading to increased production of bradykinin and further, of NO (Siragy et al., 2000). 
No difference appeared in NOx excretion between GK and Wistar controls, suggesting 
that endothelial NO production in GK rats is unaltered. Because the serum 8-
isoprostaglandin F
2α
 level only tended to be increased in GK rats on the LS diet, the 
increased oxidative stress in contrast to the case of dTGRs and mREN2 rats was 
probably not the crucial cause of the endothelial dysfunction in spontaneously diabetic 
GK rats. 
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A long-term HS diet in GK rats caused a marked increase in blood pressure 
associated with the development of cardiac hypertrophy. The HS diet also induced 
renal damage and aggravated inflammation and endothelial dysfunction, indicating 
that GK rats are sensitive to the deleterious effect of salt. This agrees with the studies 
in human beings which have demonstrated that hypertension in diabetic patients is 
often volume-dependent and salt-sensitive (Ritz & Orth, 1999). The increased urinary 
8-isoprostaglandin F
2α
 excretion in GK rats during the HS diet supports the theory that 
in GK rats the detrimental effects of high salt are associated with increased oxidative 
stress. Valsartan normalized salt-induced oxidative stress in these rats, suggesting 
that Ang II is involved in salt-induced oxidative stress in GK rats. Valsartan also 
effectively prevented a salt-induced inflammatory response by blood-pressure- 
independent mechanisms. Surprisingly, valsartan did not abolish high-salt-induced 
hypertension, endothelial dysfunction, or cardiac hypertrophy. The present findings 
suggest that the harmful effect of the HS diet in this animal model of type II diabetes 
may be, at least partially, due to increased RAS activity.  
 
In summary, increased RAS activity is involved in the pathogenesis of hypertension 
and renal failure in the spontaneously diabetic GK rat. Hypertension in this rat is salt-
sensitive. The deleterious effects of salt in GK rats are related to Ang II-induced 
oxidative stress. Valsartan prevented the salt-induced inflammatory response and 
oxidative stress in GK rats by blood-pressure-independent mechanisms.  
 
 
6.4. COX in the pathogenesis of Ang II-induced vascular 
inflammation 
 
The mREN2 rat with increased local RAS activity is characterized by hypertension and 
Ang II-induced tissue injury in the brain, heart, kidney, and vasculature (Mullins et al., 
1990; Bohm et al., 1995; Lee et al., 1996). Evidence is accumulating to indicate that the 
inflammatory response plays an important role in the pathogenesis of Ang II-induced 
vascular/tissue damage. Prostanoids are major mediators of the inflammatory response 
and are synthesized by COX from arachidonic acid. However, whether COX-synthesized 
prostanoids are involved in Ang II-induced inflammation and vascular injury is still 
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unclear. In the present study, neither the selective COX-2 inhibitor MF-tricyclic nor the 
non-selective COX-1/COX-2 inhibitor sulindac was capable of preventing Ang II-induced 
inflammatory responses or tissue damage. In contrast, both compounds showed clear 
blood-pressure-increasing effects and further aggravated Ang II-induced renal damage. 
Furthermore, RT-PCR gene-expression analysis revealed that COX-2 mRNA expression 
was down-regulated by Ang II both in the kidney and heart. Although COX inhibitors 
exerted detrimental cardiovascular and renal effects in mREN2 rats, they did not 
attenuate the therapeutic effects of the AT1 receptor antagonist losartan.  
 
The present study supports the recent clinical finding that COX-2 inhibitors may increase 
risk for cardiovascular events, for instance, through increased blood pressure (FitzGerald 
& Patrono, 2001; Mukherjee et al., 2001). An important finding of the present study was 
the close correlation between systolic blood pressure and degree of cardiac hypertrophy 
in mREN2 rats, suggesting that the development of cardiac hypertrophy in these rats is 
primarily mediated by increased pressure overload. However, the present study could 
provide no evidence for further aggravation of Ang II-induced myocardial or vascular 
lesions by COX inhibition. 
 
Although the kidneys exhibit abundant constitutive expression of COX-2 (Harris, 2000; 
Breyer & Harris, 2001), the physiological role of COX-2 in the kidney is not fully 
understood. Several studies support the notion that the renal COX-2 may regulate renin 
release as well as renal microcirculation in response to environmental factors such as 
salt and water depletion (Harris, 2000; Breyer & Harris, 2001). Recent studies have 
provided compelling evidence that endothelial- and VSMC-derived vasodilatory 
prostanoids attenuate the renal vascular response to Ang II (Imig, 2000). In the present 
study, the blood-pressure-increasing effect of COX inhibitors in mREN2 rats is likely to 
be due to derangement in the renal microcirculation and to tissue damage. 
 
COX-2 is almost exclusively expressed in the renal macula densa cells (Harris et al., 
1994; Vio et al., 1997; Hartner et al., 1998). The macula densa is directly adjoined to 
the renin-producing cells of the afferent arterioles. Macula densa-derived prostaglandins 
(Gerber et al., 1981; Greenberg et al., 1993) are well-known stimulators of renin 
synthesis and of renin secretion. However, to the best of our knowledge, the influence of 
the RAS on COX-2 expression is still unclear. In the present study, COX-2 mRNA 
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expression both in the heart and kidneys were down-regulated, whereas AT1 receptor 
blockade by losartan increased COX-2 gene expression. Regulation of COX-2 protein 
expression by RAS was also noted with COX-2 immunohistochemistry. Our findings are 
thus in good agreement with those of previous studies (Cheng et al., 1999; Harris, 2000; 
Breyer & Harris, 2001) and further support the suggestion that inhibition of COX-2 by 
Ang II could form novel indirect negative feedback control of the renin system (Wolf et 
al., 1999; Zhang et al., 1999) (Figure 6). The mechanisms by which Ang II inhibits 
COX-2 expression should be investigated in further experiments. 
 
Due to increased Ang II formation in tissues, mREN2 rats develop hypertension, cardiac 
hypertrophy, and renal damage (Mullins et al., 1990; Bohm et al., 1995; Lee et al., 1996). 
We showed recently that Ang II induces tissue damage even by blood pressure-
independent mechanisms (Mervaala et al., 2000b). Ang II generates ROS, activates the 
redox-sensitive transcription factors NF-κB and activator protein-1, and induces severe 
perivascular inflammation through AT1 receptor stimulation (Luft et al., 1999). Both COX-
1 and COX-2-derived prostanoids play important roles in mediating and terminating the 
inflammatory response (Mitchell et al., 1995; Harris, 2000; Imig, 2000; Breyer & Harris, 
2001). COX-2 can be induced in endothelial cells, fibroblasts, smooth muscle cells, and 
macrophages by proinflammatory cytokines, endotoxin, prostanoids, tumor promoters, 
mitogens, and hypoxia (Mitchell et al., 1995; Wu, 1995). Intriguingly, treatment with 
COX-2 selective inhibitors like NS398 and celecoxib, but not with the non-selective COX-
1/COX-2 inhibitor indomethacin, severely diminished early and late events of T cell 
activation, partly through NF-κB and NF-AT-transcription pathways, supporting the notion 
that selective COX-2 inhibitors may act as modulators of the immune system (Iniguez et 
al., 1999). Anti-inflammatory effects of COX-2-derived prostanoids have, however, also 
been described (Gilroy et al., 1999). It has also been claimed that COX-2 induction in 
endothelial cells may represent an important compensatory mechanism to defend 
against vascular injury (Wu, 1998b). In the present study, Ang II induced a marked 
monocyte/macrophage infiltration both in the heart and the kidneys. That the COX 
inhibitors had no detectable anti-inflammatory effects suggests that COX does not play a 
central role in the pathogenesis of the Ang II-induced inflammatory response. 
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ACE  = angiotensin II converting enzyme 
COX-2  = cyclooxygenase-2                      
JC  = juxtaglomerular 
PG  = prostaglandin 
 
Figure 6. Possible interaction between renin-angiotensin system, cyclo-
oxygenease and aldosterone (modified from Wolf et al., 1999). 
 
  
In conclusion, in mREN2 rats, COX-2 mRNA and protein expression in the heart and 
the kidneys were downregulated. Neither the selective COX-2 inhibitor MF-tricyclic nor 
the non-selective COX-1/COX-2 inhibitor sulindac had a beneficial effect on Ang II-
induced inflammation. In fact, they even further increased blood pressure and 
aggravated renal damage; however, neither COX inhibitor influenced the therapeutic 
effects of losartan in mREN2 rats. 
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Angiotensinogen
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6.5. COX in the pathogenesis of Ang II-induced vascular dysfunction 
 
Prostanoids converted by COX from arachidonic acid are also critical modulators of 
vascular tone in both physiological and pathophysiological conditions. Under normal 
physiological conditions, prostanoids produced by the COX pathway generally induce 
vasorelaxation. However, in vascular pathologies, there may be an imbalance in which 
where COX-dependent vasoconstrictors become more predominant (for review, see 
Davidge, 2001). 
 
The present study investigated the role of COX-synthesized eicosanoids in Ang II-
induced vascular dysfunction in mREN2 rats. An important finding of the present study 
was that hypertension in mREN2 rats is associated with impaired vascular 
endothelium-dependent and endothelium-independent vascular relaxation in the aorta, 
whereas the renal arterial function remained largely unchanged. Urinary NOx 
excretion, a commonly used marker of total body NO generation, was markedly 
decreased in mREN2 rats. Both MF-tricyclic and sulindac slightly reduced urinary NOx 
excretion in mREN2 rats. However, neither treatment with the COX-2 selective MF-
tricyclic nor with the non-selective COX-1/COX-2 inhibitor sulindac was capable of 
preventing Ang II-induced vascular dysfunction in mREN2 rats. Previous study 
demonstrated that contractile prostanoids synthesized by COX does not play a role in 
the depelopment of hypertension (Taddei et al., 1997). These results further indicate 
that COX also does not appear to participate in the development of Ang II-induced 
vascular dysfunction in mREN2 rats.  
 
COX-2-deficient mice developed ductus arteriosus, and 35% of the mice have died 
within 48 hours after birth (Loftin et al., 2001). Moreover, 100% of the mice deficient in 
both COX-1 and COX-2 have died with a patent ductus arteriosus within 12 hours of 
birth, indicating that both COX-2 and COX-1 have physiological roles in vessel 
development. Moreover, a recent study demonstrated that COX-2 induction in 
endothelial cells may represent an important compensatory mechanism to defend 
against vascular injury (Wu, 1998b). In mREN2 rats, both COX-2 protein and mRNA 
expression were downregulated in the heart and the kidneys. Neither MF-tricyclic nor 
sulindac provides beneficial effects in Ang II-induced pathogenesis in mTRN2 rats. The 
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present study supports the above findings and suggests that COX is not involved in Ang 
II-induced vascular injury in mREN2 rats. 
 
The relationship between increased blood pressure and vascular dysfunction in different 
forms of hypertension has been widely argued. In the present study, treatment with both 
the selective COX-2 inhibitor MF-tricyclic and the non-selective COX-1/COX-2 inhibitor 
sulindac elevated blood pressure similarly, but did not affect endothelial function in 
mREN2 rats. These results support the previous suggestion that endothelial dysfunction 
may be secondary to the hypertension (McIntyre et al., 1999; Vapaatalo et al., 2000). 
The present study also supports the recent notion that the role of COX-dependent 
modulation of vascular function in hypertension may depend on animal models and 
type of vessels (for review, see Davidge, 2001). 
 
In summary, neither prolonged treatment with the selective COX-2 inhibitor MF-
tricyclic nor with the non-selective COX-1/COX-2 inhibitor sulindac affected Ang II-
induced vascular dysfunction in mREN2 rats.  
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7. SUMMARY AND CONCLUSIONS 
 
The present study aimed at exploring the mechanisms of Ang II-induced inflammatory 
response and vascular injury, and especially the role of oxidative stress and COX-
1/COX-2 in this pathogenesis. Two transgenic strains with increased local RAS activity 
(dTGRs, mREN2 rats) as well as spontaneously diabetic Goto-Kakizaki rats served as 
experimental animals.  
 
The major conclusions are as follows: 
 
1. Ang II induces vascular dysfunction via AT1 receptor stimulation. Ang II-induced 
vascular dysfunction is mainly due to endothelial dysfunction and is associated 
with increased oxidative stress. XOR is responsible, at least in part, for Ang II-
induced ROS formation. 
 
2. In spontaneously diabetic Goto-Kakizaki rats, increased RAS activity is involved 
in the pathogenesis of endothelial dysfunction and vascular inflammation. 
 
3. The pathological changes in GK rats are salt-sensitive. AT1 receptor blockade 
prevents the salt-induced inflammatory response and oxidative stress in GK 
rats by blood pressure-independent mechanisms. 
 
4. Ang II downregulates COX-2 mRNA and protein expression. COX does not 
play a central role in the pathogenesis of Ang II-induced inflammatory response 
and vascular injury. 
 
5. Prolonged treatment with the selective COX-2 inhibitor MF-tricyclic and the 
non-selective COX-1/COX-2 inhibitor sulindac aggravates Ang II-induced 
hypertension and renal damage. 
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